SPECIAL ARTICLE

WILEY | JOURNAL OF Veterinary Emergency AND Critical Care

American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines: Small animal

Robert Goggs BVSc, DACVECC, DECVECC, PhD[1] iD | Marie-Claude Blais DVM, DACVIM[2]* iD | Benjamin M. Brainard VMD, DACVAA, DACVECC[3]* iD | Daniel L. Chan DVM, DACVECC, DECVECC, DACVN[4]* iD | Armelle M. deLaforcade DVM, DACVECC[5]* | Elizabeth Rozanski DVM, DACVIM, DACVECC[5]* | Claire R. Sharp BSc, BVMS, MS, DACVECC[6]* iD

[1]Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY

[2]Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada

[3]Department of Small Animal Medicine and Surgery, University of Georgia, Athens, GA

[4]Department Clinical Science and Services, The Royal Veterinary College, London, United Kingdom

[5]Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA

[6]School of Veterinary and Life Sciences, College of Veterinary Medicine, Murdoch University, Murdoch, WA, Australia

Correspondence
Dr. Robert Goggs, Department of Clinical Sciences, Cornell University College of Veterinary Medicine, C3-502D CPC, 930 Campus Road, Ithaca, NY 14853.
Email: r.goggs@cornell.edu

Funding information
Veterinary Emergency and Critical Care Society

*These authors contributed equally to this manuscript.

Offprints: Will not be available from the authors.

Prior presentation: This work was presented in part at the European Veterinary Emergency and Critical Care Congress, June 2018, Venice, Italy and at the International Veterinary Emergency and Critical Care Symposium, September 2018, New Orleans, LA.

Abstract

Objectives: To systematically review available evidence and establish guidelines related to the risk of developing thrombosis and the management of small animals with antithrombotics.

Design: Standardized, systematic evaluation of the literature (identified by searching Medline via PubMed and CAB abstracts) was carried out in 5 domains (Defining populations at risk; Defining rational therapeutic use; Defining evidence-based protocols; Refining and monitoring antithrombotic therapies; and Discontinuing antithrombotic therapies). Evidence evaluation was carried out using Population, Intervention, Comparison, Outcome generated within each domain questions to address specific aims. This was followed by categorization of relevant articles according to level of evidence and quality (Good, Fair, or Poor). Synthesis of these data led to the development of a series of statements. Consensus on the final guidelines was achieved via Delphi-style surveys. Draft recommendations were presented at 2 international veterinary conferences and made available for community assessment, review, and comment prior to final revisions and publication.

Settings: Academic and referral veterinary medical centers.

Results: Over 500 studies were reviewed in detail. Worksheets from all 5 domains generated 59 statements with 83 guideline recommendations that were refined during 3 rounds of Delphi surveys. A high degree of consensus was reached across all guideline recommendations.

Conclusions: Overall, systematic evidence evaluations yielded more than 80 recommendations for the treatment of small animals with or at risk of developing thrombosis. Numerous significant knowledge gaps were highlighted by the evidence reviews undertaken, indicating the need for substantial additional research in this field.

KEYWORDS
anticoagulant, antiplatelet agent, cats, dogs, thromboprophylaxis

---

INTRODUCTION

Thrombosis is commonly encountered in critically ill small animals[1-6] and causes substantial morbidity and mortality.[3,7-9] Thrombosis contributes to morbidity and mortality through promotion of inflammation[10-13] and through direct end-organ damage.[14] Thrombosis complicates the management of multiple disease processes[15] and is the primary cause of various veterinary emergency room visits.[16] Furthermore, thrombi can propagate and may increase the propensity for additional clot formation and embolization.[17-19]

The epidemiology of thrombosis in human medicine is well understood,[20-27] and the substantial economic costs entailed in the management of thrombosis are also well documented.[28-30] Such data are not available in veterinary medicine. Although the burden of disease may be less in small animals than in people, it is likely still substantial. In the United States in 2017, there were approximately 96 million cats* and 90 million dogs,† and the US pet care segment of the veterinary services market was worth $13.5 billion.‡ If thrombotic disorders account for even 0.01% of this spending, then client costs for the diagnosis and management of thrombotic complications in small animals amount to millions of US dollars annually.

In human medicine, multiple iterations of evidence-based guidelines for the management of venous[31-35] and arterial thrombosis have been published.[36,37] These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials.[38-49] Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology,[50-53] the overall burden of disease, and the most frequently associated disease processes are substantially different between people and small animals.[1,15] As such, there is a clear need for veterinary specific guidelines on the use of antithrombotics.[54-56]

The available evidence from veterinary medicine, from animal models of human disease, and where necessary from human medicine relevant to the administration, monitoring, and discontinuation of antithrombotic medications in small animals was compiled to produce a series of evidence-based guidelines that were presented and discussed at both the European Veterinary Emergency and Critical Care (EVECC) Congress and the International Veterinary Emergency and Critical Care Symposium (IVECCS) in 2018. The draft guidelines were subsequently opened to community comment, revised as necessary, and edited for consistency prior to submission for publication.

In these guidelines and in the accompanying domain summary documents, we have used the terms antithrombotic and thromboprophylaxis to encompass antiplatelet agents and antiplatelet therapy and anticoagulants and anticoagulation. Owing to an overall paucity of evidence and limited clarity in the veterinary literature, we do not differentiate the use of these medications in patients with risk factors for thrombosis but without current thrombosis from those with existing thrombosis. Rather, we refer to patients at risk for thrombosis.

MATERIALS AND METHODS

An effort to generate consensus guidelines on the use of antithrombotic drugs in small animals under the auspices of the American College of Veterinary Emergency and Critical Care (ACVECC) was initiated in 2015. At that time, the ACVECC appointed 3 committee cochairs who convened to begin assembling a larger working group of participants that might be deemed "experts." Potential contributors were solicited via an electronic mailing list, and self-identified potential collaborators were required to demonstrate an established research and publication track record in the field of hemostasis via submission of a short resumé. From this group, the consensus committee cochairs selected potential contributors who were then approved by the ACVECC Board of Regents. Subsequently, 3 additional cochairs were appointed from within this group with 1 member of the ACVECC Board of Regents acting in an ex officio capacity. The committee cochairs established 5 domains, each headed by a separate domain chair. These 5 domains were (i) Defining populations at risk (A.M.dL.), (ii) Defining rational therapeutic use (R.G.), (iii) Defining evidence-based protocols (M-C.B.), (iv) Refining and monitoring antithrombotic therapies (C.R.S.), and (v) Discontinuing antithrombotic therapies (B.M.B.).

Each domain set out specific aims from which a series of clinical questions were generated that formed the basis for evidence evaluation. A Population, Intervention, Comparison, Outcome (PICO) format was used to express the clinical questions, as previously used for the 2012 Reassessment Campaign on Veterinary Resuscitation and 2014 Partnership on Rotational Viscoelastic Test Standardization endeavors.[57,58] In brief, this method involved initially defining the patient or population of interest, specifically domesticated dogs and cats. For domains 2, 3, and 4, an assumption was made the patient populations being considered have a disease process that warrants antithrombotic drug administration. Venous and arterial thromboses were considered separately where this was rational. The intervention represented the treatment choice of interest, such as the use of the antiplatelet agent aspirin, while the comparison represents the alternative treatment choice we wished to compare, such as use of the anticoagulant enoxaparin. Where necessary, drug classes were considered collectively, such as the low molecular weight heparins (LMWHs) versus unfractionated heparin (UFH), while in other worksheets individual drugs were compared, such as clopidogrel versus aspirin. For outcome, patient-centered measures such as reductions in thrombosis, diminished organ dysfunction, or improvements in survival were prioritized in evidence evaluations over surrogate measures such as alterations in biomarkers, or the results of monitoring tests. In domain 4, which focused on monitoring tests, the tests themselves were considered as the intervention rather than as the outcome. For domain 1, a Patient Exposure Comparison Outcome format was adopted[59] with questions formatted to compare the effect of exposure to the risk factor or development of the disease (Exposure) versus remaining disease free (Comparison) on development of thrombosis (Outcome). This adapted process was thereby used to generate a list of disorders for

which antithrombotic therapy might be indicated by evaluating the strength of evidence for association of a disease with thrombosis.

Within each domain, PICO questions were assigned to individual worksheet authors. These reviewers performed the bulk of the initial work through performance of comprehensive database searches, assessments of the quality and applicability of the resultant literature, and detailed reviews of the evidence applicable to the PICO question set. The end result of each worksheet was a summary of the evidence and a guideline recommendation. Worksheets were then reviewed by domain chairs with further iterations of literature searching, manuscript review, and guideline revision performed as necessary in consultation with worksheet authors. Several worksheet authors worked within more than one domain and several of the domain chairs also contributed worksheets to other domains. Instructions for worksheet authors (Data S1), blank worksheets (Data S2) for completion, and an example completed worksheet from the Partnership on Rotational Viscoelastic Test Standardization effort were distributed to worksheet authors for guidance on the process.

Comprehensive searches of the Medline and CAB (Commonwealth Agricultural Bureau) databases were performed for each worksheet using PubMed, OVID, and Web of Knowledge and supplemented by additional searches through Google Scholar and by hand where necessary. Search strategies, inclusion and exclusion criteria, and search results were recorded in the relevant worksheets. Identified relevant studies were then reviewed and the following assessed: (i) level of evidence (LOE), (ii) methodological quality, (iii) magnitude of any observed effect, (iv) direction of support or otherwise for the question asked, (v) outcome(s) assessed, and (vi) relevance to the question asked. LOEs were allocated as for the Reassessment Campaign on Veterinary Resuscitation process,[57] such that LOE 1 represented randomized controlled trials in dogs or cats; LOE 2 represented prospective clinical studies in dogs or cats with concurrent controls, but without randomization; LOE 3 represented experimental laboratory studies in dogs or cats; LOE 4 represented clinical retrospective studies in dogs or cats with both study and control groups from a previous period in time; LOE 5 represented case series and case reports in dogs or cat without a control group; and LOE 6 represented studies in humans. Within each LOE, the quality of the study was then subjectively assessed as Good, Fair, or Poor based on descriptors from the Centre for Evidence-Based Medicine.[§]

It should be noted that because some aspects of these assessments were subjective, variation in the scores assigned to individual studies across domains is possible. In addition, while an LOE and quality score could be assigned to every study assessed, not every study was equivalently applicable to the PICO question at hand. Worksheet authors and domain chairs therefore made determinations as to the relevance of the study to the PICO question and hence some studies were classified as neutral to the PICO question, irrespective of their evidence level or quality. Some studies that did not directly address the PICO question regarding efficacy were included nonetheless, because they provided evidence for safety or adverse effects that was considered pertinent to prescribing practices.

Following evidence assessment, worksheet authors were asked to digest and weigh the evidence, to discuss the results of their review, to summarize the body of evidence, and to draft guideline recommendations. The generic format for these statements was: *Evidence from # [study design and quality] studies in dogs and # [study design and quality] studies in cats, in addition to # additional studies in humans [insert range of LOE] document improvement in [outcome measure] when [intervention] is compared to [control] for management of [disease process]. Therefore, [intervention] for management of [disease process] in [patient type] is [recommended/should be considered/not-recommended].*

Domain chairs then reviewed all worksheets and suggested revisions, edits, and additional searches as required. Draft guidelines were reviewed and revised as deemed necessary by the domain chairs. These draft guidelines were summarized and presented to the community at the 2018 EVECC Congress. Feedback provided by delegates at the EVECC Congress enabled and prompted some revision of the guidelines. These revised guidelines were then subjected to 3 rounds of a Delphi survey process[60–63] to reach consensus on the content and formulation of the final draft of the guidelines. This Delphi process was conducted anonymously over a 3-week period via an online survey instrument[¶] and involved the committee chairs and all worksheet authors. Participants were given comprehensive instructions on the conduct of the Delphi survey prior to beginning. Following each iteration, collated collective feedback from the prior round and copies of both the previous and the revised versions of the guidelines were distributed to participants (Data S3). Below each guideline, the degree of consensus achieved is presented in addition to a short narrative statement describing the rationale and listing the supporting evidence assessments. Accompanying manuscripts in this edition of the *Journal* present the PICO questions, corresponding guidelines, discuss the relevant evidence in more detail, and highlight key knowledge gaps.

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process provides guidance on quality of evidence rating and on the expression of strength of recommendations in systematic reviews, health technology assessments, and clinical practice guidelines.[64] Under the GRADE scheme, recommendations are characterized as strong or weak (conditional or discretionary) according to the supporting evidence quality and the balance between desirable and undesirable consequences of the alternative options.[65] The Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care guidelines adopt this 2-tier recommendation system and are formatted per the 2016 Surviving Sepsis Campaign.[66] Thus, strong recommendations in Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care are written as "We recommend…," whereas weak recommendations are in the format "We suggest…."

GUIDELINES

Domain 1: Defining populations at risk

1.1 | Immune-mediated hemolytic anemia (dogs only)

a. Immune-mediated hemolytic anemia (IMHA) is strongly associated with the development of thrombosis in dogs.

b. We recommend antithrombotic therapy for dogs with IMHA.

Delphi process: 13/13 panel members responding agreed (round 2). Three retrospective studies (LOE 5, Good) and 1 uncontrolled prospective study (all LOE 5, Good) suggest an association between IMHA in dogs and thrombosis, particularly pulmonary thromboembolism (PTE).[9,67–69] In addition, multiple studies (LOE 2–5, Good-Poor) suggest that IMHA in dogs is associated with a hypercoagulable state,[70–73] characterized by increased tissue factor expression,[74] platelet activation,[75,76] procoagulant microparticle release,[77] and neutrophil extracellular trap generation.[13,78]

1.2 | Protein-losing nephropathy (dogs only)

a. Protein-losing nephropathy (PLN) is associated with the development of thrombosis in dogs.

b. We recommend antithrombotic therapy for dogs with PLN.

Delphi process: 13/13 panel members responding agreed (round 2). Seventeen studies (LOE 2–5, Good-Fair) support an association between PLN and thrombosis.[14,79–94] Most of these studies lack a control group, precluding establishment of a clear cause and effect relationship. When evaluated as a whole, however, the total number of dogs with PLN described across all studies with various thrombotic conditions strongly suggests an association between PLN and pathologic thrombosis. Studies investigating hemostatic changes in dogs with PLN describe thromboembolic complications in 6% to 42% of dogs.[83–87,89,93–96]

1.3 | Pancreatitis (dogs only)

a. Severe pancreatitis, in particular acute necrotizing pancreatitis, may be associated with the development of thrombosis in dogs.

b. We suggest that antithrombotic therapy be considered for dogs with acute pancreatic necrosis, particularly when concurrent prothrombotic conditions are present.

Delphi process: 13/13 panel members responding agreed (round 2). Three studies (LOE 2–5, Poor) suggest that canine pancreatitis is associated with a hypercoagulable state,[11,97,98] although none of these studies included dogs with clinical evidence of thrombosis. One study (LOE 4, Good) suggested an overrepresentation of thrombosis in dogs with pancreatitis compared to other presenting complaints.[99] Multiple studies (LOE 3–5, Good-Poor) document concomitant pancreatitis in dogs with known thrombosis,[79–81,88,96,100–104] and acute pancreatic necrosis was the histopathologic diagnosis in 4 of these studies. It should be acknowledged that thrombosis is not reported as a complication in all pancreatitis populations.[105] The frequent presence of comorbidities in published reports also complicates the assessment of the association between pancreatitis and thrombosis in dogs.[80]

1.4 | Glucocorticoid administration (dogs only)

a. Corticosteroid administration favors a hypercoagulable state.

b. Treatment with corticosteroids may be associated with the development of thrombosis in dogs, in particular those with other risk factors for thrombosis.

c. We suggest that antithrombotic therapy be considered for dogs receiving corticosteroids where other risk factors for thrombosis exist.

Delphi process: 13/13 panel members responding agreed (round 2). No studies directly investigating the relationship between glucocorticoids and the increased risk of thrombosis in dogs were identified. The guideline is based on retrospective studies (LOE 5, Good-Fair) of thrombotic states where concurrent or recent therapy with glucocorticoids featured prominently,[14,79–81,88,102,106–108] and experimental studies (LOE 3, Fair) of healthy dogs administered oral prednisone that document generation of a hypercoagulable state.[109–112] Two prospective studies (LOE 2, Fair) provide additional indirect evidence of an association between glucocorticoid administration and thrombosis in dogs.[113,114] Studies investigating hemostatic changes secondary to glucocorticoids are lacking in cats.

1.5 | Hyperadrenocorticism (dogs only)

a. Hyperadrenocorticism (HAC) is associated with the development of thrombosis in a small subset of dogs only.

b. We suggest HAC alone does not warrant antithrombotic therapy in the majority of dogs, unless other risk factors for thrombosis exist.

Delphi process: 13/13 panel members responding agreed (round 2). Ten studies (2 LOE 4, 8 LOE 5) suggest that HAC is associated with the development of thrombosis in dogs.[79,80,88,106,107,115–119] However, all were retrospective; most did not have a control group and comorbidities were frequent. Assessing the sum of the literature, HAC is reported in 4–17% of dogs with a known thrombotic event.[79–81,88,106,107,115] Studies (LOE 2-5, Good-Fair) investigating the hemostatic profiles of dogs with HAC have reached opposing conclusions about whether a hypercoagulable state is present, suggesting the phenomenon is not universal to dogs with HAC.[120–124]

1.6 | Cancer (dogs only)

a. Cancer in dogs, in particular (adeno)carcinoma, is associated with the development of thrombosis in a small subset of dogs only.

b. There is insufficient evidence to support routine anticoagulation of dogs with cancer.

c. We suggest that antithrombotic therapy be considered for dogs with cancer where hypercoagulability is demonstrated, or where other risk factors for thrombosis exist.

Delphi process: 12/12 panel members responding agreed (round 3). Neoplasia is frequently identified as an underlying disease in retrospective studies of canine thrombosis (LOE 5, Good-Fair),[79–81,96,106,125] but thrombosis does not affect the majority of dogs with neoplasia. In addition, comorbidities and recent or concurrent glucocorticoid administration complicate the direct assessment of the risk of thrombosis in dogs with cancer. Multiple studies (LOE 2–5, Good-Poor) have documented hypercoagulability in dogs with neoplasia, particularly in carcinoma, sarcoma, and lymphoma,[126–129]

and the presence of thrombi in tumors.[130–132] Hypercoagulability in dogs with neoplasia appears to be multifactorial.[98,127,129,133–135]

1.7 | Sepsis (dogs only)

a. Sepsis is associated with the development of thrombosis in a small subset of dogs only.

b. There is insufficient evidence to support routine anticoagulation of dogs with sepsis.

c. We suggest that antithrombotic therapy be considered for dogs with sepsis where hypercoagulability is demonstrated, or where other risk factors for thrombosis exist.

Delphi process: 12/12 panel members responding agreed (round 3). Sepsis is a common disease process in retrospective studies of dogs with thrombosis,[14,79,81,88,96,106,116] but most studies lack controls (LOE 5, Good-Fair), and the direct association between sepsis and thrombosis is confounded by concurrent disease processes.[136] Hemostatic alterations consistent with hypercoagulability have been identified in dogs with sepsis.[11,12,135,137–140]

1.8 | Cerebrovascular disease

a. Cerebrovascular disease is more likely to result from a thrombotic event rather than be the cause of one.

b. We suggest that antithrombotic therapy be considered when an ischemic stroke is identified and a concurrent medical condition associated with a risk for thrombosis is present.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member felt that the guideline might be less applicable to patients with concurrent ischemic and hemorrhagic strokes.

Information provided by 3 studies (LOE 5, Fair) suggest that ischemic strokes are more likely the result of a hypercoagulable conditions than a risk factor for thrombosis themselves.[141-143] None of the dogs included in retrospective studies of PTE, arterial thromboembolism (ATE), portal vein, or splenic vein thrombosis had cerebrovascular disease.[79–81,88,102,106,107,115,116,118]

1.9 | Heart disease (cats)

a. Feline cardiomyopathy is strongly associated with a risk of ATE.

b. Cats with a history of ATE, left atrial (LA) dilation, spontaneous echocontrast, or reduced LA appendage flow velocity may be at particular risk.

c. We recommend antithrombotic therapy for cats with cardiomyopathy, particularly in those with the above risk factors.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member felt this guideline should state "we strongly recommend."

Three studies (LOE 2–4, Good-Fair) strongly support the association of feline cardiomyopathy with ATE.[144-146] The cumulative risk of ATE at 1, 5, and 10 years was 3.5%, 9.5%, and 11.3%, respectively, in cats with hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy compared to 0.0%, 0.4%, and 0.7%, respectively, in

apparently healthy cats (LOE 2, Good).[144] Five other studies (LOE 2–4, Good-Fair) suggest that feline cardiac disease accompanied by spontaneous echocontrast, LA dilation, reduced LA function, and low flow velocities may portend ATE or death.[82,147–150]

1.10 | Heart disease (dogs)

a. Canine cardiac diseases are not associated with a high risk for the development of thrombosis.

b. We suggest that antithrombotic therapy be considered in individual dogs where other risk factors for thrombosis exist.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member felt that if canine structural heart disease was not associated with thrombosis that the presence of another minor risk factor should not prompt antithrombotic therapy. Only 1 study was identified linking cardiac disease in dogs to the development of thrombosis (LOE 4, Fair).[108] Most retrieved studies (LOE 2–5, Good–Fair) were considered neutral to the relevant PICO question,[14,101,106,116,151–153] and a similar quantity of evidence (LOE 4–5, Fair–Poor) refuted a link as suggested one.[4,88,115]

1.11 | We define high risk for thrombosis as

a. Dogs with IMHA or PLN.

b. Cats with cardiomyopathy and associated risk factors (see Section 1.9).

c. Dogs or cats with >1 disease/risk factor for thrombosis (eg, pancreatitis with sepsis).

Delphi process: 13/13 panel members responding agreed (round 2). As discussed above, strong associations exist between thrombosis and IMHA and PLN in dogs and with cardiomyopathy in cats. Where the association is weaker, reference to human scoring systems and guidelines provides a rational approach to risk stratification.[154–156] It is likely that risk factors for thrombosis are cumulative.[154] The risk of bleeding versus the risk of thrombosis should be considered for each individual patient before deciding upon initiation or discontinuation of antithrombotics. Individual risk should account for the underlying condition(s), the inflammatory state of the animal, planned procedures, the likelihood the underlying condition can be resolved in a timely fashion, and the impact of medications such as glucocorticoids on thrombotic risk.

1.12 | We define low/moderate risk for thrombosis as

a. Dogs or cats with a single risk factor/disease.

b. Dogs or cats with known risk factor conditions that, with treatment, are likely to resolve in days to weeks.

Delphi process: 13/13 panel members responding agreed (round 2). See Section 1.11 for key supporting evidence.

Domain 2: Defining rational therapeutic use

2.1 | Antiplatelet agents versus anticoagulants for VTE (dogs)

a. We suggest that anticoagulants may be more effective than antiplatelet agents for venous thromboembolism (VTE) prevention in dogs in general and in dirofilariasis specifically.

Delphi process: 14/14 panel members responding agreed (round 1). Evidence from 1 study in dogs (LOE 3, Good) suggested that heparin was superior to aspirin for prevention of thrombus formation under venous shear.[157] An additional study (LOE 3, Good) evaluated thrombus formation in the low-shear setting of the pulmonary arterial system in dogs with experimentally induced dirofilariasis and demonstrated that neither aspirin or aspirin and dipyridamole protect against PTE in dirofilariasis.[158]

2.2 | Antiplatelet agents versus anticoagulants for VTE (cats)

a. No evidence-based recommendations can be made regarding the use of antiplatelet agents for VTE in cats.

b. We suggest that anticoagulants rather than antiplatelet agents be used for the prevention of VTE in cats.

Delphi process: 14/14 panel members responding agreed (round 1). Two publications were identified (LOE 3, Good) suggesting that aspirin has limited, if any, efficacy for prevention of pulmonary thromboembolism due to dirofilariasis in cats.[159,160] Evidence for efficacy of anticoagulants in VTE in cats is presented elsewhere (Sections 3.2.10, 3.2.12, 3.2.14, 3.3.8, 3.3.10, and 3.3.12).

2.3 | Antiplatelet agents versus anticoagulants for ATE (dogs)

a. We suggest that antiplatelet agents may be more effective than anticoagulants for the prevention of ATE in dogs.

b. We suggest that anticoagulants may also be effective for prevention of ATE in dogs.

Delphi process: 12/14 panel members responding agreed (round 1). One panel member felt the rarity of ATE in dogs limited the evidence base and hence increased the risk associated with this guideline. One panel member felt that thrombosis in canine coronary vessels might be distinct from thrombosis in the aorta.

Three studies (all LOE 3, Good) suggested that anticoagulants were inferior to antiplatelet agents in the setting of provoked arterial thrombosis.[161-163] Multiple studies (19 LOE 3, Good; 1 LOE 3, Fair) also suggest efficacy of anticoagulants for arterial thrombosis in dogs, however.[164-183]

2.4 | Antiplatelet agents versus anticoagulants for ATE (cats)

a. We recommend that antiplatelet agents be used for the prevention of ATE in cats.

b. No evidence-based recommendations can be made regarding the use of anticoagulants for ATE in cats.

Delphi process: 14/14 panel members responding agreed (round 1). Evidence supporting the use of antiplatelet agents for ATE in cats is presented elsewhere (Sections 3.2.6, 3.2.8, and 3.3.4). Three publications reported use of anticoagulants in cats with ATE (LOE 4, Fair), but all were judged to be neutral to the PICO question.[82,184,185]

2.5 | Clopidogrel versus aspirin (dogs)

a. There is insufficient evidence to make strong recommendations regarding clopidogrel versus aspirin in dogs.

b. We suggest that clopidogrel may be more effective than aspirin in dogs at risk for ATE.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member agreed with (a) of Section 2.5.a. but felt the evidence in favor of clopidogrel was insufficient to support (b) of Section 2.5.b.

Evidence for efficacy of aspirin and clopidogrel for ATE in dogs is presented elsewhere (Sections 3.3.1 and 3.3.3). One study (LOE 1, Fair) directly compared aspirin with clopidogrel for thromboprophylaxis in dogs, but was underpowered to detect clinically relevant differences in efficacy.[186] One experimental study (LOE 3, Fair) suggests clopidogrel is superior to aspirin in a model of coronary artery thrombosis.[187]

2.6 | Clopidogrel versus aspirin (cats)

a. We recommend that clopidogrel be used instead of aspirin in cats at risk for ATE.

b. There is no evidence on which to base recommendations regarding the use of aspirin or clopidogrel in cats at risk for VTE.

Delphi process: 13/13 panel members responding agreed (round 2). One prospective study in cats (LOE 1, Good) provides evidence that clopidogrel is superior to aspirin for thromboprophylaxis in cats with previous aortic thromboembolic events.[188]

2.7 | New antiplatelet agents versus clopidogrel or aspirin (dogs)

a. There is insufficient evidence to make recommendations regarding the use of new antiplatelet agents versus clopidogrel or aspirin in dogs.

b. We suggest that both abciximab and ticagrelor appear safe and may be efficacious antiplatelet agents in dogs.

Delphi process: 13/13 panel members responding agreed (round 2). No clinical studies evaluating novel antiplatelet agents in dogs were identified. Four experimental studies (all LOE 3, Fair) suggest efficacy for novel antiplatelet agents in dogs,[189-192] but of these, only ticagrelor and abciximab are commercially available.

2.8 | New antiplatelet agents versus clopidogrel or aspirin (cats)

a. There is insufficient evidence to make recommendations regarding the use of new antiplatelet agents versus clopidogrel or aspirin in cats.

b. We suggest that abciximab appears safe and may be efficacious as an antiplatelet agent in cats.

Delphi process: 13/13 panel members responding agreed (round 2). No clinical studies evaluating novel antiplatelet agents in cats were identified. In 1 experimental study (LOE 3, Fair), abciximab demonstrated efficacy in a feline model of arterial injury.[193]

2.9 | UFH versus LMWH (dogs)

a. There is insufficient evidence to make strong recommendations regarding the use of UFH versus LMWH in dogs.

b. We suggest that LMWH may be used in preference to UFH because of the positive safety profile of LMWH and more reliable bioavailability of the LMWH products compared to UFH.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member felt that (b) of Section 2.9.b. was not justifiable because of the cost and greater difficulty monitoring LMWH. Another panel member agreed with the statement, but commented that (b) of Section 2.9.b. was most reasonable in a hospital setting.

There is a paucity of information directly comparing LMWH to UFH in dogs at risk of spontaneous thrombosis. Five studies comparing LMWH with UFH in experimental thrombosis models (all LOE 3, Good) demonstrate that LMWH is comparable or superior to UFH and is associated with lower bleeding tendency.[167,194–197]

2.10 | UFH versus LMWH (cats)

a. No evidence-based recommendations can be made regarding the use of UFH versus LMWH in cats.

b. We suggest that LMWH may be used in preference to UFH because of the documented efficacy of LMWH and the positive safety profile of LMWH.

Delphi process: 13/13 panel members responding agreed (round 2). No articles directly addressed the relevant PICO question. One study (LOE 3, Fair) demonstrated an antithrombotic effect of enoxaparin in a feline venous stasis model.[198] Multiple studies (5 LOE 3, Fair; 1 LOE 4, Fair) suggest that LMWHs are safe and have reproducible pharmacokinetics in cats.[184,199–203]

2.11 | Direct Xa inhibitors versus UFH (dogs)

a. There is insufficient evidence to make strong recommendations regarding the use of the direct Xa inhibitors versus UFH in dogs.

b. We suggest the direct Xa inhibitors may be used in preference to UFH based on evidence of equivalent efficacy, combined with reliable pharmacokinetics and the ease of oral dosing.

Delphi process: 12/12 panel members responding agreed (round 3).

Three experimental studies in canine models of vessel occlusion (all LOE 3, Good) demonstrate at least equivalent efficacy for the direct Xa inhibitors compared to UFH.[173,204,205] Various studies (1 LOE 1 Fair; 3 LOE 3, Good–Fair; and 1 LOE 5, Fair) suggest rivaroxaban is safe and may be efficacious in dogs,[206–210] but evidence comparing the direct Xa inhibitors with UFH in dogs with spontaneous disease is lacking.

2.12 | Direct Xa inhibitors versus UFH (cats)

a. No evidence-based recommendations can be made regarding the use of the direct Xa inhibitors versus UFH in cats.

b. We suggest that the direct Xa inhibitors can be considered in cats based on reliable pharmacokinetics and a favorable preliminary safety profile.

Delphi process: 12/12 panel members responding agreed (round 3). No studies directly addressed the relevant PICO question. Two pharmacokinetic–pharmacodynamic (PK–PD) studies (LOE 3, Good)[211,212] suggest that rivaroxaban and apixaban are well tolerated in cats and have reproducible PK–PD parameters.

2.13 | Direct Xa inhibitors versus LMWH (dogs)

a. There is insufficient evidence to make strong recommendations regarding the use of the direct Xa inhibitors versus LMWH in dogs.

b. We suggest that use of either the direct Xa inhibitors or LMWH in dogs is reasonable.

Delphi process: 13/13 panel members responding agreed (round 2). No prospective randomized clinical studies were identified comparing these 2 drug classes in dogs. One experimental study (LOE 3, Good) demonstrated that a direct Xa inhibitor had equivalent efficacy to enoxaparin for prevention of arterial and venous thrombosis.[181] Seven studies (all LOE 3, Good–Fair) of direct Xa inhibitors suggest these drugs are safe, orally active, and have reliable and reproducible PK–PD parameters in dogs.[208–210,213–216]

2.14 | Direct Xa inhibitors versus LMWH (cats)

a. No evidence-based recommendations can be made regarding the use of the direct Xa inhibitors versus LMWH in cats.

b. We suggest that use of either the direct Xa inhibitors or LMWH in cats is reasonable.

Delphi process: 13/13 panel members responding agreed (round 2). No studies directly addressed the relevant PICO question. Two PK–PD studies (both LOE 3, Good)[211,212] suggest that rivaroxaban and apixaban are well tolerated in cats and have reproducible PK–PD parameters.

2.15 | UFH versus warfarin and LMWH versus warfarin (dogs and cats)

a. There is insufficient evidence to make strong recommendations regarding the efficacy of heparin products versus warfarin in dogs or cats.

b. We suggest that UFH or LMWH be used in preference to warfarin (see other recommendations regarding the choice between UFH and LMWH).

Delphi process: 12/12 panel members responding agreed (round 3). There is insufficient evidence comparing UFH or LMWH with warfarin in dogs or cats at risk of thrombosis. There is evidence supporting the use of the drug classes individually, which suggests their use may be preferable in certain diseases of dogs or cats at risk for thrombosis. The efficacy of UFH, LMWHs, and warfarin are discussed elsewhere.

2.16 | Direct Xa inhibitors versus warfarin (dogs and cats)

a. No evidence-based recommendation can be made regarding the efficacy of direct Xa inhibitors versus warfarin in dogs or cats.

b. We suggest that the direct Xa inhibitors be used in preference to warfarin in both dogs and cats.

Delphi process: 12/12 panel members responding agreed (round 3). There is insufficient evidence comparing direct Xa inhibitors with warfarin in dogs or cats at risk of thrombosis. There is evidence supporting the use of the drug classes individually, which suggests their use may be preferable in certain diseases of dogs or cats at risk for thrombosis. Large scale studies in people suggest that the direct Xa inhibitors are at least as effective as warfarin and are associated with better safety profiles, specifically in terms of a reduction in the risk of life-threatening hemorrhage.[41,44,217]

2.17 | Combination anticoagulant and antiplatelet therapy for VTE (dogs)

a. We suggest that administration of aspirin or clopidogrel in addition to LMWH or individually adjusted UFH therapy may be considered in dogs at high risk of VTE, where the risk of clot formation is felt to outweigh the increased risk of bleeding resulting from combination therapy.

Delphi process: 14/14 panel members responding agreed (round 1). Very little evidence was identified that addressed the relevant PICO question. A single study of dogs (LOE 4, Fair) suggested an outcome advantage for UFH combined with aspirin compared to UFH in dogs with IMHA,[218] but the comparison is confounded by differences in illness severity between groups. The guideline recommendation is primarily based on data reviewed in this and other domains and represent the current practice of the committee.

2.18 | Combination anticoagulant and antiplatelet therapy for VTE (cats)

a. There is insufficient evidence to make strong recommendations regarding combination anticoagulant and antiplatelet agent therapy in cats.

b. We suggest that combination therapy may be considered where there is a high risk of thrombosis and the risk of clot formation is felt to outweigh the increased risk of bleeding resulting from combination therapy.

Delphi process: 13/13 panel members responding agreed (round 2). No studies directly address the relevant PICO question in cats. The guideline recommendation is primarily based on data reviewed in this and other domains and represent the current practice of the committee.

2.19 | Combination antiplatelet and anticoagulant therapy for ATE (dogs)

a. There is insufficient evidence to make strong recommendations for or against the use of combination antiplatelet and anticoagulant therapy in dogs at risk for ATE.

b. We suggest that administration of clopidogrel or aspirin with LMWH may be considered in dogs at risk for ATE.

Delphi process: 13/13 panel members responding agreed (round 2). No studies directly compare combined anticoagulant and antiplatelet therapy over antiplatelet therapy alone in dogs. Comparison of outcomes in 2 separate case series (LOE 5, Good–Fair),[108,116] where dogs received antiplatelet therapy alone, with outcomes of dogs in 3 separate case series (LOE 5, Good–Fair),[4,108,207] where dogs received combination therapies, suggests lower recurrence rates in dogs receiving combination therapy. It should be recognized that comparison of patient outcomes in these studies in this manner is strictly hypothesis generating, however. A meta-analysis of 6 trials comprising 29,667 people with acute coronary syndromes suggests use of direct oral anticoagulants in addition to antiplatelet therapy reduced ischemic events.[219]

2.20 | Combination antiplatelet and anticoagulant therapy for ATE (cats)

a. No evidence-based recommendations can be made regarding the addition of anticoagulants to antiplatelet agents for ATE in cats.

b. We suggest that administration of clopidogrel in combination with LMWH may be considered in cats at risk for ATE.

Delphi process: 12/12 panel members responding agreed (round 3). No studies directly addressed the relevant PICO question. Comparisons of recurrence rates from 3 separate retrospective studies in cats (LOE 4, Fair) suggest that multimodal therapy compared to antiplatelet therapy alone may decrease recurrence of feline ATE.[82,184,220] It should be recognized that comparison of patient outcomes in these studies in this manner is strictly hypothesis generating. On the basis of separate evidence of efficacy for clopidogrel and for LMWH in cats,[184,188,198] this combination of drugs represents the first choice of the panel if combination therapy is selected for an individual patient.

Domain 3: Defining evidence-based protocols

3.1 | Aspirin (dogs)

a. We suggest that oral aspirin may be effective for prevention of ATE in dogs.

b. No evidence-based recommendations can be made for a specific aspirin dosage in dogs.

c. We suggest that aspirin be given for 2–3 days before full therapeutic effects of aspirin are anticipated, although commencement of aspirin therapy after an arterial insult may still be effective at preventing thrombosis.

d. No recommendations can be made for, or against, use of aspirin for VTE in dogs.

Delphi process: 12/13 panel members responding agreed (round 2).
One panel member felt that a dosage recommendation should be made to provide clinicians with guidance.

Multiple studies in various thrombosis model systems demonstrate that aspirin effectively prevents induced ATE in dogs when commenced at least 2 days prior to the thrombogenic insult. Seven studies (all LOE 3, Good–Poor) suggest that protocolized aspirin therapy is more effective than no aspirin therapy in endarterectomy and angioplasty models.[221-228] Two studies (both LOE 3, Good–Fair) using reocclusion models suggested aspirin is efficacious following therapeutic fibrinolysis in dogs.[229,230] Multiple studies (all LOE 3, Good–Poor) in graft models suggest aspirin is efficacious in dogs but the aspirin dose used varied widely among studies, with only a limited number directly comparing dosages.[223,231-239] The reported dose range is very wide, however between 0.5 and 15 mg/kg per day it is reportedly effective. There is inadequate evidence to assess the efficacy of aspirin in dogs in clinical situations predisposing to thromboembolism.

3.2 | Aspirin (cats)

a. We recommend against aspirin as a sole antithrombotic in cats at risk for ATE.

b. No recommendations can be made concerning appropriate aspirin dosage in cats.

Delphi process: 13/13 panel members responding agreed (round 2).
Clinically, aspirin as the sole treatment in cats at risk of ATE is associated with a 75% incidence of recurrence within 12 months of an event (LOE 1, Good) and is inferior to clopidogrel for feline ATE thromboprophylaxis.[188] Two retrospective studies (LOE 4, Poor) also identified ATE recurrence in 20–28% cases.[82,220] Multiple experimental studies offer conflicting assessments of the inhibitory effect of aspirin on feline platelet function. Seven studies (LOE 2–5, Poor) suggest efficacy for aspirin in cats,[159,160,240-244] while 6 studies (LOE 1 and 3, Good–Poor) suggest aspirin is poorly effective against ATE in cats.[82,188,220,245-247] This may be attributable to varying dosages and differing outcome measures and test methodologies.

3.3 | Clopidogrel (dogs)

a. We recommend clopidogrel at 1.1–3 mg/kg PO every 24 hours for the prevention of ATE in dogs.

b. We suggest a single oral loading dose (eg, 4–10 mg/kg) may be useful for obtaining therapeutic plasma concentrations more rapidly.

c. No recommendations can be made for, or against, use of clopidogrel as a sole agent for VTE in dogs.

Delphi process: 12/13 panel members responding agreed (round 2).

One panel member felt that the risks of clot formation should be weighed against the risk of gastrointestinal bleeding resulting from administration of a loading dose.

In dogs, 17 papers (LOE 3, Good–Fair) suggest efficacy of clopidogrel.[187,189-192,248-259] Of these publications, 10 (all LOE 3, Good–Fair) suggest in vivo efficacy against provoked arterial thrombosis. Reported dosages vary considerably, with efficacy varying between dogs, model systems, and thrombotic stimulus. Ex vivo tests suggest 1.1 mg/kg PO once a day inhibits ADP-induced platelet aggregation.[257] A dose of 4 mg/kg PO once a day after a 10 mg/kg loading dose provides protection against provoked arterial thrombosis.[256] No evidence for or against the efficacy of clopidogrel in venous thrombosis in dogs was identified.

3.4 | Clopidogrel (cats)

a. We recommend clopidogrel at 18.75 mg total PO every 24 hours for prevention of ATE in cats.

b. We suggest a single oral loading dose (eg, 37.5 mg total) may be useful for obtaining therapeutic plasma concentrations more rapidly.

c. No recommendations can be made for, or against, use of clopidogrel for VTE in cats.

Delphi process: 13/13 panel members responding agreed (round 2).
In cats, 8 studies (LOE 1–4, Good–Poor) suggest clopidogrel is effective in cats.[185,188,260-265] Three studies (LOE 1–4, Good–Poor) suggest in vivo efficacy against provoked arterial thrombosis.[185,188,260] In contrast to dogs, there is very good consistency in the dosages used in the feline studies (18.75 mg PO q 24 h, equivalent to 3–6 mg/kg for a typical cat). One Randomized clinical trial (RCT) (LOE 1, Good) comparing clopidogrel with aspirin in feline ATE suggests clopidogrel should be used in cats with ATE, in preference to aspirin.[188] No evidence for or against the efficacy of clopidogrel in venous thrombosis in cats was identified.

3.5 | Warfarin (dogs)

a. We suggest that warfarin should not be used in dogs because it inconsistently improves outcomes and is commonly associated with bleeding complications.

Delphi process: 11/14 panel members responding agreed (round 1).
One panel member felt the guideline should specify "for thromboprophylaxis." One panel member felt warfarin could still be considered with some patients and compliant clients. One panel member dissented but an alternative suggestion was not made.

In dogs, 10 studies (LOE 1–5, Good–Poor) suggest efficacy of warfarin in vivo in dogs or using in vitro tests.[4,266-274] Seven studies (LOE 3–5, Good–Poor) document a lack of efficacy of warfarin in preventing thrombosis and/or demonstrate bleeding complications.[236,271,272,275-277] Three additional studies (LOE 3, Good–Poor) highlight the narrow therapeutic index of warfarin, the alterations in warfarin pharmacokinetics over time,[278] high levels of protein binding,[279] and the effects of coadministration of aspirin.[266]

3.6 | Warfarin (cats)

a. No evidence-based recommendations can be made regarding the use of warfarin in cats at risk for thrombosis.

b. We suggest that warfarin should not be used in cats because of marked interindividual variation coupled with a narrow therapeutic index.

Delphi process: 13/14 panel members responding agreed (round 1). One panel member dissented but an alternative suggestion was not made.

Two studies (both LOE 3, Fair–Poor) suggest warfarin has some efficacy in cats.[280,281] Three studies (LOE 3–5, Good–Poor) suggest a lack of efficacy for warfarin in the cat.[282–284]

3.7 | Unfractionated heparin (dogs)

a. UFH can be effectively administered by the IV or SC routes in dogs.

b. Optimal UFH dose likely varies in individual dogs to maximize antithrombotic effects and minimize hemorrhagic complications.

c. We suggest an initial IV dosing scheme of 100 U/kg bolus, then 480–900 U/kg every 24 hours (20–37.5 U/kg every hour) constant rate infusion in dogs.

d. We suggest an initial SC dosage of UFH of 150–300 U/kg every 6 hours in dogs.

e. We recommend that UFH is not administered by inhalation or PO in dogs.

Delphi process: 13/13 panel members responding agreed (round 2). Eight studies (LOE 1–4, Good-Fair) suggest UFH is efficacious in dogs.[8,285–289] The optimal dosing scheme is unestablished, however, and a consistent, effective, and safe fixed UFH dose likely does not exist. Individual dose adjustment based on anti-Xa monitoring appears effective in dogs (LOE 1, Good).[286] Inhaled UFH does not appear effective in dogs (LOE 3, Fair).[290]

3.8 | Unfractionated heparin (cats)

a. Only a SC route of administration of UFH has been investigated in cats.

b. We suggest an initial SC dosage of UFH of 250 U/kg every 6 hours in cats.

Delphi process: 13/13 panel members responding agreed (round 2). Only 1 study (LOE 3, Fair) was identified investigating the effect of UFH 250 U/kg every 6 hours in cats.[202] There are insufficient data to suggest superiority or inferiority of UFH compared to other regimens in cats.

3.9 | Dalteparin (dogs)

a. We suggest an initial SC dosage of 100–175 U/kg every 8 hours in dogs.

b. Minor bleeding may be noted at the doses reported above, but serious bleeding is unlikely.

Delphi process: 13/13 panel members responding agreed (round 2). Four studies (LOE 3–5, Fair-Poor) suggest some of efficacy for dalteparin in dogs.[287,291–293] Most assume that human target therapeutic anti-Xa range (0.5–1.0) is an appropriate target in dogs, but the relationship between anti-Xa activity and clinical efficacy in dogs has not been firmly established. Bleeding complications in dogs are uncommon and typically minor, but overdosage can result in potentially life-threatening bleeding.[293]

3.10 | Dalteparin (cats)

a. In cats, frequent SC administration is likely necessary for maintenance of the human target anti-Xa range.

b. We suggest lower dosages compared to dogs may be acceptable at increased frequency, for example, 75 U/kg SC every 6 hours.

c. Bleeding complications, usually minor and self-limiting, may occur with a variety of dosing schemes.

Delphi process: 14/14 panel members responding agreed (round 1). Six studies (LOE 3–5, Fair-Poor) report usage of dalteparin in cats but were considered neutral to the relevant PICO question.[184,199,200,202,203,244] A dosing scheme of 75–150 U/kg administered subcutaneously every 6 hours may be reasonable,[199,202] but the relationship between anti-Xa activity and clinical efficacy in cats has not been firmly established. Bleeding complications, usually self-limiting and minor in nature, may occur with a variety of dosing schemes in cats.[184,199,202]

3.11 | Enoxaparin (dogs)

a. We suggest enoxaparin at a dosage of 0.8 mg/kg SC every 6 hours is safe and well tolerated in dogs.

b. This dose may not achieve anti-Xa levels considered to be therapeutic in people in all breeds of dog.

c. Only minor bleeding complications have been reported in association with enoxaparin use in dogs.

Delphi process: 13/13 panel members responding agreed (round 2). Five studies (LOE 3–5, Good-Poor) suggest enoxaparin is effective in dogs,[287,294–297] with 0.8 mg/kg SC every 6 hours the most commonly reported protocol.[294–296] There is no evidence suggesting that enoxaparin is superior to other drugs or protocols and doubt has been raised about the uniformity of enoxaparin's activity at 0.8 mg/kg SC every 6 hours across all dog breeds.[298]

3.12 | Enoxaparin (cats)

a. We suggest enoxaparin at a dosage of 0.75–1 mg/kg SC every 6 12 hours should be considered in cats with a risk of VTE.

b. We suggest enoxaparin be administered every 6 hours to reduce interindividual variation in peak anti-Xa activity.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member felt that every 6 hours and every 12 hours dosing were not equivalent, indicating comparisons of every 6 hours with every 12 hours dosing using clinically relevant endpoints are lacking.

Three studies (all LOE 3, Fair) suggest efficacy for enoxaparin in healthy cats.[198,201,202] The most commonly used protocol is 0.75–1 mg/kg SC every 6–12 hours. A dose of 0.75 mg/kg every 6 hours is documented to generate reproducible peak anti-Xa activity within the human target range.[201] Enoxaparin at 1 mg/kg SC every 12 hours in cats at risk of thrombosis may be effective[198] but inadequate to increase anti-Xa activity.[202]

3.13 | Fondaparinux (dogs and cats)

a. No studies of fondaparinux in dogs were identified.

b. A dose of fondaparinux of 0.06 or 0.20 mg/kg SC every 12 hours was sufficient to achieve a peak plasma anti-Xa activity in cats considered effective in people, without bleeding complications.

Delphi process: 14/14 panel members responding agreed (round 1). There are no studies evaluating fondaparinux in dogs. A single dose determination study (LOE 3, Fair) in 6 cats suggests anti-Xa levels comparative to those considered effective in humans can be achieved safely.[299]

3.14 | Rivaroxaban (dogs)

a. Based on preliminary data, rivaroxaban appears safe and well tolerated in dogs.

b. We suggest a dosage of 1–2 mg/kg per day in dogs.

Delphi process: 13/13 panel members responding agreed (round 2). Two studies (LOE 2–4, Fair) reported on the use of rivaroxaban in clinical patients, but data are insufficient to determine if rivaroxaban is efficacious in dogs at risk for thrombosis.[206,207] Two studies (LOE 2–3, Fair) suggest efficacy for rivaroxaban in vitro and in healthy dogs administered the drug using ex vivo tests.[208,209]

3.15 | Rivaroxaban (cats)

a. Based on preliminary data, rivaroxaban appears safe and well tolerated in cats.

b. We suggest a dosage of 0.5–1 mg/kg per day in cats.

Delphi process: 12/12 panel members responding agreed (round 3). A single PK–PD study (LOE 2, Fair) in cats was identified.[211] No reports of feline clinical patients receiving rivaroxaban were retrieved.

Domain 4: Refining and monitoring antithrombotic therapies

4.1 | Aspirin

a. Adjusting therapy to achieve platelet inhibition via platelet aggregometry in dogs receiving aspirin therapy can be considered.

b. Some evidence suggests that in dogs receiving aspirin, platelet inhibition detectable via aggregometry (various agonists) is associated with reduced risk of ATE.

c. Monitoring techniques are currently too varied to provide uniform recommendations at this time.

Delphi process: 14/14 panel members responding agreed (round 1).

Several LOE 3 studies suggest that platelet inhibition detectable by aggregometry is associated with reduced risk of ATE; however, there is considerable variation in the agonists used for aggregometry in different studies.[226–229,233,234] Two publications (LOE 3, Poor), reporting different aspects of the same study, directly addressed the PICO question.[159,160] These investigations suggest aspirin dosing individually adjusted based on aggregometry provided superior thromboprophylaxis relative to fixed dose aspirin in an experimental model of dirofilariasis. Although dose-adjusted aspirin was superior, the overall efficacy was limited, prompting the authors to conclude that aspirin cannot be recommended for treatment of heartworm disease in cats. The general applicability of these data is uncertain. Numerous studies have assessed the effect of aspirin on platelet function in healthy cats, using a variety of in vitro methods.[241,245,264,300,301] Results are variable, which may reflect methodologic differences, but overall, they suggest aspirin has limited antiplatelet efficacy in cats, particularly against potent platelet agonists.

4.2 | Warfarin

a. We suggest that warfarin should not be used in dogs or in cats.

b. If warfarin is used, we recommend monitoring warfarin therapy ideally with PTINR (PT—prothrombin time; INR—international normalized ratio) to achieve a target of 2–3 or 1.5–2.0 times the baseline PT.

c. Close therapeutic monitoring, particularly early in the course of therapy, is indicated to maximize efficacy and reduce the risk of complications.

Delphi process: 11/12 panel members responding agreed (round 3). One panel member felt that the guideline should indicate that continuous (ideally weekly) monitoring is advisable given the reported variability in warfarin pharmacokinetic and the potential for interactions with concomitant medications.

No studies in dogs specifically addressed the relevant PICO question. Two LOE 2 (Fair) studies evaluated warfarin therapy in dogs undergoing cardiac valve replacement and monitored dogs with PT. These studies suggested some therapeutic efficacy of warfarin when adjusted to achieve target INR. Of the 20 dogs reported across the 2 studies, 9 dogs died of confirmed or suspected thrombosis despite INR monitoring of warfarin therapy.[273,276] Two other studies (both LOE 3, Fair) reported the use of warfarin in dogs undergoing vascular grafting ($n = 27$ total), adjusted based on the PT. Overall graft patency rates were good, but 1 dog died of hemorrhage.[272,302] One study (LOE 3, Poor) involved the administration of warfarin to cats at risk of thrombosis that underwent therapeutic monitoring.[282] That study did not specifically address the relevant PICO question, but did demonstrate a lack of association between PT prolongation and the therapeutic efficacy of warfarin. A PK–PD study of warfarin in healthy cats documented wide variations in PK–PD parameters that would likely necessitate individual dose algorithms to ensure optimal warfarin dosing in cats.[280]

4.3 | Unfractionated heparin

a. We recommend anti-Xa activity for UFH monitoring in dogs because evidence supporting the use of other monitoring tests (eg, activated clotting time, activated partial thromboplastin time, thromboelastography, and Sonoclot) is limited at this time.

b. An anti-Xa target of 0.35–0.7U/mL is recommended in dogs to minimize thrombosis risk and improve outcome, although minor hemorrhage may still occur.

c. There is insufficient evidence to make a strong recommendation for a specific anti-Xa target in cats.

d. We suggest an anti-Xa target of 0.35–0.7U/mL is reasonable in cats until more evidence is available.

Delphi process: 13/13 panel members responding agreed (round 2).

Data from a single randomized controlled trial (LOE 1, Fair) suggest that there is an outcome benefit from adjusting UFH doses based upon therapeutic monitoring.[286] That study and an experimental study (LOE 3, Fair) support the use of an anti-Xa activity range of 0.35–0.7 IU/mL.[287] The Helmond et al study[286] and a second prospective study (LOE 2, Fair) indicate that anti-Xa activity is the criterion (gold) standard for UFH monitoring.[8] Additional studies (LOE 3, Fair–Poor) suggest that other hemostatic tests may have a role in monitoring UFH in dogs but clinical utility remains to be demonstrated.[285,289,303–307] No studies in cats directly addressed the PICO question. One study suggests that the anti-Xa assay is the standard method for UFH monitoring in cats and that achievement of anti-Xa activity of 0.3–0.7 U/L causes anticoagulation in cats.[202]

4.4 | Low molecular weight heparin

a. There is insufficient evidence to make strong recommendations for therapeutic monitoring of LMWH in dogs or cats.

b. We suggest adjusting therapy in dogs, targeting anti-Xa levels of 0.5–1.0U/mL 2–4 hours after dose can be considered.

Delphi process: 12/12 panel members responding agreed (round 3).

Four experimental studies in dogs (LOE 3, Good–Fair) addressed the PICO question, but provide limited evidence relevant to clinical practice.[181,194,196,308] Various monitoring tests for LMWH in dogs including anti-Xa activity, PT, activated partial thromboplastin time, thrombin time, activated clotting time, thromboelastography, and the Sonoclot assay have been evaluated.[181,194,196,288,292,308,309] The anti-Xa assay appears to be the most sensitive test of the anticoagulant effect of LMWHs in dogs.[292,294,303,309–311] Two studies (LOE 3, Fair–Poor) demonstrated a protective effect of achieving an anti-Xa activity of 0.55–0.9 U/mL in dogs using LMWH.[312,313] Studies in healthy dogs (LOE 3, Poor) targeting anti-Xa activities of 0.5–1.0 IU/mL have demonstrated safety at this dose.[294,303] No studies in cats specifically addressed either of the relevant PICO questions and there is considerable variation in the anti-Xa activity achieved in cats after SC administration of LMWH; however, peak anti-Xa activity appears to occur at around 2 hours after SC dosing in this species.[199,200,202,203]

Domain 5: Discontinuing antithrombotic therapies

5.1 | Discontinuation of antithrombotic agents

a. In patients at high risk for thrombosis, anticoagulation should not be discontinued for invasive procedures.

b. In patients at low to moderate risk for thrombosis, consideration may be given for discontinuation of anticoagulation prior to invasive procedures.

The risk for bleeding must be balanced with the risk for thrombosis. In patients that require invasive procedures (eg, surgery, biopsy), this balance is particularly acute and will depend on the underlying risk factors for thrombosis and hemorrhage as well as the type of procedure. In procedures where hemorrhage may be catastrophic (eg, neurosurgery) or unable to be easily controlled (eg, percutaneous renal biopsy), discontinuation or alteration of therapy is prudent. For less-invasive procedures (eg, dental extraction and truncal mass removal), or those where hemorrhage may be addressed through tamponade (eg, surgery on a peripheral limb), anticoagulant therapy may continue through the procedure if there is a high risk of thrombosis without anticoagulation. These patients may also be switched to other medications with favorable pharmacokinetics for the periprocedural period. Consideration for the risk of rebound hypercoagulability should be given when planning complete or temporary cessation of therapy.

5.2 | Antiplatelet agent discontinuation 5–7 days prior to an elective procedure versus no discontinuation (high risk)

a. We recommend that antiplatelet therapy with a single antiplatelet agent should be continued.

b. We recommend discontinuing 1 agent if animals are receiving dual antiplatelet therapy.

c. We suggest that these patients are at increased risk of bleeding and that close attention be paid to surgical hemostasis.

Delphi process: 13/13 panel members responding agreed (round 2).

No veterinary studies specifically addressed the relevant PICO question and hence multiple studies from human medicine (LOE 6, Fair) were extrapolated to generate this guideline.[314–328] The guideline represents a balance of the increased risk of thrombosis associated with drug discontinuation in patients with high-risk conditions[329] or where multiple risk factors exist compared to the perceived lower risk of surgical hemorrhage that may result from ongoing platelet inhibition of hemorrhage.[324,325,330] In addition, dual antiplatelet therapy with aspirin and clopidogrel can result in significantly more hemorrhage compared with antiplatelet monotherapy.[331,332]

5.3 | Antiplatelet agent discontinuation 5–7 days prior to an elective procedure versus no discontinuation (low/moderate risk)

a. We recommend that antiplatelet agents should be discontinued prior to the planned procedure.

Delphi process: 13/13 panel members responding agreed (round 2).

No veterinary studies specifically addressed the relevant PICO question and hence multiple studies from human medicine (LOE 6, Fair) were extrapolated to generate this guideline.[314–328] The guideline represents a balance of the perceived low risk of thrombosis associated with drug discontinuation in this patient population compared to the risk of perioperative bleeding.

5.4 | UFH/LMWH discontinuation 24 hours prior to an elective procedure versus no discontinuation (high risk)

a. We recommend that heparin therapy should not be discontinued.

b. We recommend that surgery be planned to occur at nadir of anticoagulant effect (approximately 6–8 hours after prior dose if given by subcutaneous injection).

c. We suggest that these patients are at increased risk of bleeding and that close attention be paid to surgical hemostasis.

Delphi process: 12/12 panel members responding agreed (round 3). No veterinary studies specifically addressed the relevant PICO question and hence multiple studies from human medicine (LOE 6, Good) were extrapolated to generate this guideline.[314–328] Patients at high risk of thrombosis are considered more likely to suffer consequences from thrombosis following discontinuation of heparin therapy than they are to suffer morbidity or mortality from procedure related hemorrhage.[333] Timing surgery to occur around the nadir of anticoagulant effect[334] coupled with scrupulous surgical hemostasis may mitigate the bleeding risk.

5.5 | UFH/LMWH discontinuation 24 hours prior to an elective procedure versus no discontinuation (low/moderate risk)

a. We recommend that consideration may be given to taper (UFH) or stop (LMWH) therapy prior to a procedure.

Delphi process: 13/13 panel members responding agreed (round 2). No veterinary studies specifically addressed the relevant PICO question. Evidence summary is as given in Section 5.5. In patients at low to moderate risk of thromboembolic disease, tapering or discontinuing heparin therapy may limit hemorrhage during procedures without significantly increasing the risk of thrombosis.

5.6 | Antiplatelet agent discontinuation 5–7 days prior to surgery versus 24 hours (high risk)

a. We recommend against withdrawing antiplatelet agents within 5 days of a procedure.

Delphi process: 13/13 panel members responding agreed (round 2). Four veterinary studies (LOE 3, Fair)[257,260,300,335] and 3 from human medicine (LOE 6, Good)[336–338] provided evidence for this guideline. In patients receiving irreversible antiplatelet agents, a 24-hour withdrawal time is unlikely to be different than not discontinuing the agent at all in patients at high risk for thrombosis[339,340] and hence this guideline reflects as given in Section 5.2.

5.7 | Antiplatelet agent discontinuation 5–7 days prior to surgery versus 24 hours (low/moderate risk)

a. We recommend that antiplatelet agents be discontinued within 5 days of a procedure.

Delphi process: 12/12 panel members responding agreed (round 3). Four veterinary studies (LOE3, Fair)[257,260,300,335] and 3 from human medicine (LOE 6, Good)[336–338] provided evidence for this guideline. Platelet lifespans are 7–9 days in people,[341] 6.0 ±1.1 days in dogs,[342] and possibly shorter in cats.[343] However, platelet function may be acceptable to provide adequate surgical hemostasis prior to 5–7 days following cessation of medications, as functional platelets are introduced into the bloodstream on a continuous basis. In patients receiving irreversible antiplatelet agents, but with a low risk of thrombosis, progress toward a return of normal platelet function may be achieved prior to surgery by drug discontinuation and hence this guideline reflects 5.3 above.

5.8 | Restarting antithrombotic therapy 24 hours post-surgery versus 3–5 days (high risk patient)

a. We recommend that in patients at high risk, antithrombotic therapy should be restarted as soon as possible after surgery provided there is no evidence of ongoing bleeding.

5.9 | Restarting antithrombotic therapy 24 hours postsurgery versus 3–5 days (low/moderate risk patient)

a. No evidence-based recommendation can be made for patients at low/moderate risk.

b. We suggest that in patients at low/moderate risk, antithrombotic therapy be restarted once there is no evidence of ongoing bleeding.

5.10 | Restarting antithrombotic therapy 24 hours postsurgery versus 3–5 days (patients that develop thrombosis)

a. We recommend that antithrombotic therapy should be initiated immediately in patients that develop thrombosis in the postoperative period.

Delphi process: 13/13 panel members responding agreed (round 2). Five studies in human medicine (LOE 6, Good–Fair) provided evidence for guideline (a) in Section 5.10, which is based on an assessment of the likelihood of thrombosis compared to bleeding.[273,344] High-risk patients are more likely to be harmed by delays in administration of thromboprophylaxis than by mild postoperative bleeding.[345–347] There was insufficient evidence to make a recommendation regarding low-risk patients, but the panel has provided a consensus recommendation for guidance. One veterinary study (LOE 5, Good) supports prompt initiation of thromboprophylaxis in patients that develop thrombosis postoperatively.[274]

5.11 | Discontinuation of antithrombotic therapy in patients where an in situ arterial blood clot is no longer identifiable

a. We recommend that if the underlying causative conditions have resolved, antithrombotic therapy should be discontinued following thrombus resolution.

b. In patients with unknown underlying conditions or where these conditions cannot be cured or resolved, we recommend antithrombotic therapy should be continued indefinitely.

Delphi process: 13/13 panel members responding agreed (round 2). Evidence from 2 veterinary studies (LOE 1–5, Good) suggests that patients at high risk of arterial thrombosis may have recurrent thrombi despite antithrombotic medications.[82,188] Several studies (LOE 1–3, Good–Poor) suggest that patients with a noncurable predisposing condition should not have therapy discontinued[119,207,348] and discontinuation is not recommended in such patients. Cessation of antithrombotic therapy, upon resolution of thrombosis, when the underlying cause was resolved, is supported by 3 case reports and a case series (LOE 4–5, Poor).[117,274,349,350]

5.12 | Discontinuation of antithrombotic therapy in patients where an in situ venous blood clot is no longer identifiable

a. We recommend that if the underlying causative conditions have resolved, that antithrombotic therapy should be discontinued following thrombus resolution.

b. In patients with unknown underlying conditions or where these conditions cannot be cured or resolved, we recommend antithrombotic therapy should be continued indefinitely.

c. In patients with a low or moderate risk of thrombosis, we suggest that the risk of hemorrhage and the ability of the animal to tolerate antithrombotic therapy should be weighed against the risk of recurrence of the prothrombotic condition.

Delphi process: 12/13 panel members responding agreed (round 2). One panel member felt it was not clear that dogs receiving immunosuppressive corticosteroids for a condition such as IMHA that was resolving would require indefinite antithrombotics.

There are few quality studies assessing the long-term treatment of venous thrombi in veterinary patients. The available evidence is composed of case series (LOE 4, Good–Fair) and single case reports (LOE 5, Fair) and supports discontinuation of antithrombotics, upon resolution of the thrombus, when the underlying cause could be eliminated or had resolved.[14,117,244,351,352] In humans, studies (LOE 6, Good–Fair) support discontinuation of anticoagulation in patients with risk factors for thrombosis that can be resolved or removed.[353,354] Multiple veterinary case reports (LOE 5, Poor) support indefinite use of antithrombotics in patients with chronic (noncurable) underlying causes particularly for the treatment of venous thrombi.[5,14,119,355–359]

5.13 | Weaning of UFH therapy

a. We recommend that if UFH is administered as an IV constant rate infusion, it should be tapered (weaned) rather than abruptly discontinued.

b. Clinicians should consider weaning UFH therapy administered by the subcutaneous route.

Delphi process: 14/14 panel members responding agreed (round 1). A single veterinary study (LOE 3, Good)[360] and 5 from human medicine (LOE 6, Good–Fair) provided evidence for this guideline.[361–365] A rebound hypercoagulable syndrome is described following abrupt discontinuation of UFH therapy in people and may increase the incidence of thrombotic events. A recent pilot study (LOE 3, Fair) also suggested increased thrombin production following discontinuation of subcutaneous UFH in dogs.[360]

5.14 | Weaning of LMWH therapy

a. Clinicians do not need to wean LMWH therapy prior to discontinuation.

Delphi process: 14/14 panel members responding agreed (round 1). No veterinary studies specifically addressed the relevant PICO question. Data from 4 studies from human medicine (LOE 6, Good–Fair) were extrapolated to generate this guideline. The rebound hypercoagulability described for UFH has not been consistently observed following enoxaparin discontinuation,[366–368] although a single report was identified suggesting this might occur with dalteparin, but to a lesser extent than with UFH.[365]

## 5.15 | Weaning of direct Xa inhibitor therapy

a. Clinicians should consider weaning direct oral Xa inhibitor therapies.

Delphi process: 14/14 panel members responding agreed (round 1). No relevant veterinary studies were identified and hence 3 studies from human medicine (LOE 6, Poor) were extrapolated to generate this guideline.[369–371] Overall, there is insufficient evidence to confirm or refute a rebound effect following discontinuation of the direct Xa inhibitors. Several human case reports describe thrombotic events following discontinuation of rivaroxaban.[369–371] There are no data in dogs or cats on rivaroxaban withdrawal to provide guidance. Until more data are available, the panel suggests weaning of these therapies is reasonable.

CONCLUSIONS

These guidelines on the indications for, and prescribing, monitoring and discontinuation of antithrombotics in small animals represent the current consensus of a panel of veterinary experts. These guidance statements are based on assessments of the evidence available at the time of writing including clinical and epidemiological evidence, experimental studies, and human guidelines where appro-

priate. Consensus statements aim to provide guidance on potentially contentious topics, particularly where data informing clinical decisions are limited or conflicting. As will be apparent from the supporting evidence statements above, there are very few level 1 or 2 studies (randomized controlled clinical trials and prospective controlled clinical studies) in this field and the overall evidence quality was not optimal in many cases. This necessarily limits the strength of the recommendations that can be made and it is likely that some of our recommendations will be controversial. The panel also recognizes that the evidence assessments and hence the resulting guidelines have likely been biased by our collective clinical experience.

The panel's hope for these guidelines and the domain summary manuscripts is that they provide a basis for antithrombotic prescribing in small animals. We recognize and strongly believe that such guidance does not, and should not, replace the careful consideration by qualified and committed veterinarians assessing and making management decisions for individual patients. This field also continues to evolve and novel research findings potentially relevant to this topic were being presented at international meetings even as these guidelines were being prepared. As a result, the panel recognizes that these guidelines will not remain current for long and that new information will necessitate revision in the foreseeable future. The panel is therefore committed to reappraising the literature in 5 years' time (2024) and to generating revised guidelines at that time.

ACKNOWLEDGMENTS

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest.

Footnotes

* Statista, Inc. New York, NY. Number of cats in the U.S. 2000–2017/2018. https://www.statista.com/statistics/198102/cats-in-the-united-states-since-2000/. Accessed November 21, 2018.

† Statista, Inc. New York, NY. Number of dogs in the U.S. 2000–2017. https://www.statista.com/statistics/198100/dogs-in-the-united-states-since-2000/. Accessed November 21, 2018.

‡ Veterinarian's Money Digest 2018, Intellisphere, LLC, Cranbury, NJ. https://www.vmdtoday.com/news/united-states-leads-global-veterinary-services-market-growth. Accessed November 21, 2018.

§ The Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Services, University of Oxford. https://www.cebm.net/2014/06/critical-appraisal/. Accessed November 21, 2018.

¶ Qualtrics, LLC, Provo, UT. www.qualtrics.com

ORCID

Robert Goggs BVSc, DACVECC, DECVECC, PhD [iD]
https://orcid.org/0000-0001-7446-6987
Marie-Claude Blais DVM, DACVIM [iD]
https://orcid.org/0000-0003-0877-4425
Benjamin M. Brainard VMD, DACVAA, DACVECC [iD]
https://orcid.org/0000-0003-4299-2936
Daniel L. Chan DVM, DACVECC, DECVECC, DACVN [iD]
https://orcid.org/0000-0001-5213-0390
Claire R. Sharp BSc, BVMS, MS, DACVECC [iD]
https://orcid.org/0000-0002-1797-9783

REFERENCES

1. Kidd L, Mackman N. Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia. *J Vet Emerg Crit Care*. 2013;*23*:3-13.

2. Hogan DF. Feline Cardiogenic Arterial Thromboembolism: Prevention and Therapy. *Vet Clin North Am Small Anim Pract*. 2017;*47*:1065-1082.

3. Hogan DF, Brainard BM. Cardiogenic embolism in the cat. *J Vet Cardiol*. 2015;*17*(Suppl 1):S202-S214.

4. Winter RL, Sedacca CD, Adams A, Orton EC. Aortic thrombosis in dogs: presentation, therapy, and outcome in 26 cases. *J Vet Cardiol*. 2012;*14*:333-342.

5. Rogers CL, O'Toole TE, Keating JH, et al. Portal vein thrombosis in cats: 6 cases (2001-2006). *J Vet Intern Med*. 2008;*22*:282-287.

6. Brainard BM, Brown AJ. Defects in coagulation encountered in small animal critical care. *Vet Clin North Am Small Anim Pract*. 2011;*41*:783-803, vii.

7. Panek CM, Nakamura RK, Bianco D. Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases. *J Vet Emerg Crit Care*. 2015;*25*:273-277.

8. Breuhl EL, Moore G, Brooks MB, Scott-Moncrieff JC. A prospective study of unfractionated heparin therapy in dogs with primary immune-mediated hemolytic anemia. *J Am Anim Hosp Assoc*. 2009;*45*:125-133.

9. Carr AP, Panciera DL, Kidd L. Prognostic factors for mortality and thromboembolism in canine immune-mediated hemolytic anemia: a retrospective study of 72 dogs. *J Vet Intern Med*. 2002;*16*:504-509.

10. Jeffery U, LeVine DN. Canine neutrophil extracellular traps enhance clot formation and delay lysis. *Vet Pathol*. 2018;*55*:116-123.

11. Kim SD, Baker P, DeLay J, Wood RD. Thrombomodulin expression in tissues from dogs with systemic inflammatory disease. *Vet Pathol*. 2016;*53*:797-802.

12. McMichael MA, O'Brien M, Smith SA. Hypercoagulability in dogs with blastomycosis. *J Vet Intern Med*. 2015;*29*:499-504.

13. Jeffery U, Kimura K, Gray R, et al. Dogs cast NETs too: Canine neutrophil extracellular traps in health and immune-mediated hemolytic anemia. *Vet Immunol Immunopathol*. 2015;*168*:262-268.

14. Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996). *J Am Vet Med Assoc*. 1998;*213*:220-224.

15. de Laforcade A. Diseases associated with thrombosis. *Top Companion Anim Med*. 2012;27:59-64.

16. Williams TP, Shaw S, Porter A, Berkwitt L. Aortic thrombosis in dogs. *J Vet Emerg Crit Care*. 2017;27:9-22.

17. Morris TA, Marsh JJ, Chiles PG, et al. Embolization itself stimulates thrombus propagation in pulmonary embolism. *Am J Physiol Heart Circ Physiol*. 2004;287:H818-H822.

18. Goto S. Propagation of arterial thrombi: local and remote contributory factors. *Arterioscler Thromb Vasc Biol*. 2004;24:2207-2208.

19. Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. *Am J Med*. 1998;104:381-385.

20. Ekker MS, Boot EM, Singhal AB, et al. Epidemiology, aetiology, and management of ischaemic stroke in young adults. *Lancet Neurol*. 2018;17:790-801.

21. Turetz M, Sideris AT, Friedman OA, et al. Epidemiology, pathophysiology, and natural history of pulmonary embolism. *Semin Intervent Radiol*. 2018;35:92-98.

22. Baumann Kreuziger L, Jaffray J, Carrier M. Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults. *Thromb Res*. 2017;157:64-71.

23. Favate AS, Younger DS. Epidemiology of Ischemic Stroke. *Neurol Clin*. 2016;34:967-980.

24. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. *Blood*. 2013;122:1712-1723.

25. Cushman M. Epidemiology and risk factors for venous thrombosis. *Semin Hematol*. 2007;44:62-69.

26. Roger VL. Epidemiology of myocardial infarction. *Med Clin North Am*. 2007;91:537-552, ix.

27. Bulger CM, Jacobs C, Patel NH. Epidemiology of acute deep vein thrombosis. *Tech Vasc Interv Radiol*. 2004;7:50-54.

28. Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. *Clinicoecon Outcomes Res*. 2015;7:451-462.

29. Grosse SD, Nelson RE, Nyarko KA, et al. The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. *Thromb Res*. 2016;137:3-10.

30. Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the american heart association. *Circulation*. 2017;135:e146-e603.

31. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*. 2012;141:e419S-e496S.

32. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. *J Thromb Haemost*. 2013;11:56-70.

33. Konstantinides SV, Torbicki A, Agnelli G, et al. ESC Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur Heart J*. 2014;35:3033-3080.

34. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease CHEST guideline and expert panel report. *Chest*. 2016;149:315-352.

35. Afshari A, Ageno W, Ahmed A, et al. European Guidelines on perioperative venous thromboembolism prophylaxis: executive summary. *Eur J Anaesthesiol*. 2018;35:77-83.

36. Levine GN, Bates ER, Bittl JA, et al. ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. *Circulation*. 2016;134:e123-e155.

37. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2018;49:e46-e110.

38. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007;357:2001-2015.

39. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009;361:1045-1057.

40. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med*. 2009;361:2342-2352.

41. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med*. 2010;363:2499-2510.

42. Buller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med*. 2012;366:1287-1297.

43. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. *N Engl J Med*. 2012;367:1297-1309.

44. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*. 2013;369:799-808.

45. Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med*. 2013;369:1406-1415.

46. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. *Circulation*. 2014;129:764-772.

47. Zeymer U, Mochmann HC, Mark B, et al. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). *JACC Cardiovasc Interv*. 2015;8(1 Pt B):147-154.

48. Jackson LR 2nd, Ju C, Zettler M, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. *JACC Cardiovasc Interv*. 2015;8:1880-1889.

49. Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. *Circulation.* 2016;*134*:1603-1612.

50. Garosi LS. Cerebrovascular disease in dogs and cats. *Vet Clin North Am Small Anim Pract.* 2010;*40*:65-79.

51. Garosi LS, McConnell JF. Ischaemic stroke in dogs and humans: a comparative review. *J Small Anim Pract.* 2005;*46*:521-529.

52. Kitrell D, Berkwitt L. Hypercoagulability in dogs: pathophysiology. *Compend Contin Educ Vet.* 2012;*34*:E1-E5.

53. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, et al. Animal models of cardiovascular diseases. *J Biomed Biotechnol.* 2011;*2011*:497841.

54. Lunsford KV, Mackin AJ. Thromboembolic therapies in dogs and cats: an evidence-based approach. *Vet Clin North Am Small Anim Pract.* 2007;*37*:579-609.

55. Smith SA. Antithrombotic therapy. *Top Companion Anim Med.* 2012;*27*:88-94.

56. Kitrell D, Berkwitt L. Hypercoagulability in dogs: treatment. *Compend Contin Educ Vet.* 2012;*34*:E3.

57. Boller M, Fletcher DJ. RECOVER evidence and knowledge gap analysis on veterinary CPR. Part 1: Evidence analysis and consensus process: collaborative path toward small animal CPR guidelines. *J Vet Emerg Crit Care.* 2012;*22*(Suppl 1):S4-S12.

58. Goggs R, Brainard B, de Laforcade AM, et al. Partnership on Rotational ViscoElastic Test Standardization (PROVETS): evidence-based guidelines on rotational viscoelastic assays in veterinary medicine. *J Vet Emerg Crit Care.* 2014;*24*:1-22.

59. Richardson WS, Wilson MC, Nishikawa J, Hayward RS. The well-built clinical question: a key to evidence-based decisions. *ACP J Club.* 1995;*123*:A12-A13.

60. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. *Am J Public Health.* 1984;*74*:979-983.

61. Jairath N, Weinstein J. The Delphi methodology (part one): a useful administrative approach. *Can J Nurs Adm.* 1994;*7*:29-42.

62. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv Nurs.* 2000;*32*:1008-1015.

63. Powell C. The Delphi technique: myths and realities. *J Adv Nurs.* 2003;*41*:376-382.

64. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ.* 2008;*336*:924-926.

65. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.* 2011;*64*:383-394.

66. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2016. *Crit Care Med.* 2017;*45*:486-552.

67. Klein MK, Dow SW, Rosychuk RA. Pulmonary thromboembolism associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). *J Am Vet Med Assoc.* 1989;*195*:246-250.

68. McManus PM, Craig LE. Correlation between leukocytosis and necropsy findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994-1999). *J Am Vet Med Assoc.* 2001;*218*:1308-1313.

69. Goggs R, Chan DL, Benigni L, et al. Comparison of computed tomography pulmonary angiography and point-of-care tests for pulmonary

70. Fenty RK, Delaforcade AM, Shaw SE, O'Toole TE. Identification of hypercoagulability in dogs with primary immune-mediated hemolytic anemia by means of thromboelastography. *J Am Vet Med Assoc.* 2011;*238*:463-467.

71. Goggs R, Wiinberg B, Kjelgaard-Hansen M, Chan DL. Serial assessment of the coagulation status of dogs with immune-mediated haemolytic anaemia using thromboelastography. *Vet J.* 2012;*191*:347-353.

72. Sinnott VB, Otto CM. Use of thromboelastography in dogs with immune-mediated hemolytic anemia: 39 cases (2000-2008). *J Vet Emerg Crit Care.* 2009;*19*:484-488.

73. Hamzianpour N, Chan DL. Thromboelastographic assessment of the contribution of platelets and clotting proteases to the hypercoagulable state of dogs with immune-mediated hemolytic anemia. *J Vet Emerg Crit Care.* 2016;*26*:295-299.

74. Piek CJ, Brinkhof B, Teske E, et al. High intravascular tissue factor expression in dogs with idiopathic immune-mediated haemolytic anaemia. *Vet Immunol Immunopathol.* 2011;*144*:346-354.

75. Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. *J Vet Intern Med.* 2006;*20*:682-686.

76. Zoia A, Gerou-Ferriani M, Drigo M, Caldin M. Case-control study of plasma mean platelet component concentration and survival analysis for dogs with immune-mediated hemolytic anemia. *J Am Vet Med Assoc.* 2018;*252*:1384-1392.

77. Kidd L, Geddings J, Hisada Y, et al. Procoagulant microparticles in dogs with immune-mediated hemolytic anemia. *J Vet Intern Med.* 2015;*29*:908-916.

78. Lawson C, Smith SA, O'Brien M, McMichael M. Neutrophil extracellular traps in plasma from dogs with immune-mediated hemolytic anemia. *J Vet Intern Med.* 2018;*32*:128-134.

79. Respess M, O'Toole TE, Taeymans O, et al. Portal vein thrombosis in 33 dogs: 1998–2011. *J Vet Intern Med.* 2012;*26*:230-237.

80. Laurenson MP, Hopper K, Herrera MA, Johnson EG. Concurrent diseases and conditions in dogs with splenic vein thrombosis. *J Vet Intern Med.* 2010;*24*:1298-1304.

81. Van Winkle TJ, Liu SM, Hackner SG. Clinical and pathological features of aortic thromboembolism in 36 dogs. *J Vet Emerg Crit Care.* 1993;*3*:13-21.

82. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. *J Vet Intern Med.* 2003;*17*:73-83.

83. Donahue SM, Brooks M, Otto CM. Examination of hemostatic parameters to detect hypercoagulability in dogs with severe protein-losing nephropathy. *J Vet Emerg Crit Care.* 2011;*21*:346-355.

84. Slauson DO, Gribble DH. Thrombosis complicating renal amyloidosis in dogs. *Vet Pathol.* 1971;*8*:352-363.

85. Cook AK, Cowgill LD. Clinical and pathological features of protein-losing glomerular disease in the dog: a review of 137 cases (1985-1992). *J Am Anim Hosp Assoc.* 1996;*32*:313-322.

86. Slauson DO, Gribble DH, Russell SW. A clinicopathological study of renal amyloidosis in dogs. *J Comp Pathol.* 1970;*80*:335-343.

87. Rasedee A, Feldman BF, Washabau R. Naturally occurring canine nephrotic syndrome is a potentially hypercoagulable state. *Acta Vet Scand.* 1986;*27*:369-377.

88. Hardie EM, Vaden SL, Spaulding K, Malarkey DE. Splenic infarction in 16 dogs: a retrospective study. *J Vet Intern Med.* 1995;*9*:141-148.

thromboembolism diagnosis in dogs. *J Small Anim Pract.* 2014;*55*:190-197.

89. Segev G, Cowgill LD, Jessen S, et al. Renal amyloidosis in dogs: a retrospective study of 91 cases with comparison of the disease between Shar-Pei and non-Shar-Pei dogs. *J Vet Intern Med*. 2012;26:259-268.

90. Ritt MG, Rogers KS, Thomas JS. Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog. *J Am Anim Hosp Assoc*. 1997;33:385-391.

91. Clements CA, Rogers KS, Green RA, Loy JK. Splenic vein thrombosis resulting in acute anemia: an unusual manifestation of nephrotic syndrome in a Chinese shar pei with reactive amyloidosis. *J Am Anim Hosp Assoc*. 1995;31:411-415.

92. Green RA, Kabel AL. Hypercoagulable state in three dogs with nephrotic syndrome: role of acquired antithrombin III deficiency. *J Am Vet Med Assoc*. 1982;181:914-917.

93. Lennon EM, Hanel RM, Walker JM, Vaden SL. Hypercoagulability in dogs with protein-losing nephropathy as assessed by thromboelastography. *J Vet Intern Med*. 2013;27:462-468.

94. White CR, Langston C, Hohenhaus AE, et al. Evaluation of the relationship between clinical variables and thromboelastographic findings in dogs with protein-losing nephropathy. *J Vet Emerg Crit Care*. 2016;26:74-79.

95. Littman MP, Dambach DM, Vaden SL, Giger U. Familial protein-losing enteropathy and protein-losing nephropathy in Soft Coated Wheaten Terriers: 222 cases (1983-1997). *J Vet Intern Med*. 2000;14:68-80.

96. Lamb CR, Wrigley RH, Simpson KW, et al. Ultrasonographic diagnosis of portal vein thrombosis in four dogs. *Vet Radiol Ultrasound*. 1996;37:121-129.

97. Jacinto AML, Ridyard AE, Aroch I, et al. Thromboembolism in dogs with protein-losing enteropathy with non-neoplastic chronic small intestinal disease. *J Am Anim Hosp Assoc*. 2017;53:185-192.

98. Spodsberg EH, Wiinberg B, Jessen LR, et al. Endogenous fibrinolytic potential in tissue-plasminogen activator-modified thromboelastography analysis is significantly decreased in dogs suffering from diseases predisposing to thrombosis. *Vet Clin Pathol*. 2013;42:281-290.

99. Hess RS, Saunders HM, Van Winkle TJ, et al. Clinical, clinicopathologic, radiographic, and ultrasonographic abnormalities in dogs with fatal acute pancreatitis: 70 cases (1986-1995). *J Am Vet Med Assoc*. 1998;213:665-670.

100. Adrian AM, Twedt DC, Kraft SL, Marolf AJ. Computed tomographic angiography under sedation in the diagnosis of suspected canine pancreatitis: a pilot study. *J Vet Intern Med*. 2015;29:97-103.

101. Klainbart S, Kelmer E, Vidmayer B, et al. Peripheral and central venous blood glucose concentrations in dogs and cats with acute arterial thromboembolism. *J Vet Intern Med*. 2014;28:1513-1519.

102. Van Winkle TJ, Bruce E. Thrombosis of the portal vein in eleven dogs. *Vet Pathol*. 1993;30:28-35.

103. Rodríguez V, Guisado A, Weiss L, et al. Tromboembolismo aórtico secundario a una pancreatitis. *Argos*. 2011;134:42-43.

104. Narak J, Graff EC, Saile K, Tillson DM. Surgical removal of a canine aortic thromboembolism secondary to pancreatitis. *Case Rep Vet Med*. 2015;2015:1-7.

105. Papa K, Mathe A, Abonyi-Toth Z, et al. Occurrence, clinical features and outcome of canine pancreatitis (80 cases). *Acta Vet Hung*. 2011;59:37-52.

106. LaRue MJ, Murtaugh RJ. Pulmonary thromboembolism in dogs: 47 cases (1986-1987). *J Am Vet Med Assoc*. 1990;197:1368-1372.

107. Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985–1995. *J Vet Intern Med*. 1999;13:338-345.

108. Lake-Bakaar GA, Johnson EG, Griffiths LG. Aortic thrombosis in dogs: 31 cases (2000-2010). *J Am Vet Med Assoc*. 2012;241:910-915.

109. Rose L, Dunn ME, Bedard C. Effect of canine hyperadrenocorticism on coagulation parameters. *J Vet Intern Med*. 2013;27:207-211.

110. Romao FG, Campos EF, Mattoso CR, Takahira RK. Hemostatic profile and thromboembolic risk in healthy dogs treated with prednisone: a randomized controlled trial. *BMC Vet Res*. 2013;9:268.

111. O'Kell AL, Grant DC, Panciera DL, et al. Effects of oral prednisone administration with or without ultralow-dose acetylsalicylic acid on coagulation parameters in healthy dogs. *Am J Vet Res*. 2012;73:1569-1576.

112. Flint SK, Abrams-Ogg AC, Kruth SA, et al. Independent and combined effects of prednisone and acetylsalicylic acid on thromboelastography variables in healthy dogs. *Am J Vet Res*. 2011;72:1325-1332.

113. Bauer N, Moritz A. Characterisation of changes in the haemostasis system in dogs with thrombosis. *J Small Anim Pract*. 2013;54:129-136.

114. Dengate AL, Morel-Kopp MC, Beatty JA, et al. Differentiation between dogs with thrombosis and normal dogs using the overall hemostasis potential assay. *J Vet Emerg Crit Care*. 2016;26:446-452.

115. Winter RL, Budke CM. Multicenter evaluation of signalment and comorbid conditions associated with aortic thrombotic disease in dogs. *J Am Vet Med Assoc*. 2017;251:438-442.

116. Boswood A, Lamb CR, White RN. Aortic and iliac thrombosis in six dogs. *J Small Anim Pract*. 2000;41:109-114.

117. Ramsey CC, Burney DP, Macintire DK, Finn-Bodner S. Use of streptokinase in four dogs with thrombosis. *J Am Vet Med Assoc*. 1996;209:780-785.

118. Burns MG, Kelly AB, Hornof WJ, Howerth EW. Pulmonary artery thrombosis in three dogs with hyperadrenocorticism. *J Am Vet Med Assoc*. 1981;178:388-393.

119. Teshima T, Hara Y, Taoda T, et al. Cushing's disease complicated with thrombosis in a dog. *J Vet Med Sci*. 2008;70:487-491.

120. Kol A, Nelson RW, Gosselin RC, Borjesson DL. Characterization of thrombelastography over time in dogs with hyperadrenocorticism. *Vet J*. 2013;197:675-681.

121. Wong CJ, Koch M, Behling-Kelly EL. Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs. *Res Vet Sci*. 2017;111:1-8.

122. Jacoby RC, Owings JT, Ortega T, et al. Biochemical basis for the hypercoagulable state seen in Cushing syndrome;discussion 1006–7. *Arch Surg*. 2001;136:1003-1006.

123. Klose TC, Creevy KE, Brainard BM. Evaluation of coagulation status in dogs with naturally occurring canine hyperadrenocorticism. *J Vet Emerg Crit Care*. 2011;21:625-632.

124. Feldman BF, Rasedee A, Feldman EC. Haemostatic abnormalities in canine Cushing's syndrome. *Res Vet Sci*. 1986;41:228-230.

125. Thawley VJ, Sanchez MD, Drobatz KJ, King LG. Retrospective comparison of thromboelastography results to postmortem evidence of thrombosis in critically ill dogs: 39 cases (2005-2010). *J Vet Emerg Crit Care*. 2016;26:428-436.

126. Andreasen EB, Tranholm M, Wiinberg B, et al. Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression. *Acta Vet Scand*. 2012;54:3.

127. Kristensen AT, Wiinberg B, Jessen LR, et al. Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. *J Vet Intern Med*. 2008;22:140-147.

128. Kol A, Marks SL, Skorupski KA, et al. Serial haemostatic monitoring of dogs with multicentric lymphoma. *Vet Comp Oncol.* 2015;13:255-266.

129. Vilar Saavedra P, Lara Garcia A, Zaldivar Lopez S, Couto G. Hemostatic abnormalities in dogs with carcinoma: a thromboelastographic characterization of hypercoagulability. *Vet J.* 2011;190:e78-e83.

130. de la Fuente C, Pumarola M, Blasco E, et al. Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers in canine gliomas. *Vet J.* 2014;200:387-392.

131. Font C, de la Fuente C, Pumarola M, et al. Canine intracranial meningiomas: Immunohistochemical evaluation of tissue factor, fibrin/fibrinogen and D-dimers. *Vet J.* 2015;206:426-428.

132. Golombiewski A, Gutberlet K, Rudolph R. Immunohistological assessment of fibrin deposition and thrombus formation in canine mammary neoplasia. *J Comp Pathol.* 1997;117:177-183.

133. Gruber EJ, Catalfamo JL, Stokol T. Role of tissue factor expression in thrombin generation by canine tumor cells. *Am J Vet Res.* 2016;77:404-412.

134. McNiel EA, Ogilvie GK, Fettman MJ, Salman MD. Platelet hyperfunction in dogs with malignancies. *J Vet Intern Med.* 1997;11:178-182.

135. Kuzi S, Segev G, Haruvi E, Aroch I. Plasma antithrombin activity as a diagnostic and prognostic indicator in dogs: a retrospective study of 149 dogs. *J Vet Intern Med.* 2010;24:587-596.

136. Marschner CB, Kristensen AT, Rozanski EA, et al. Diagnosis of canine pulmonary thromboembolism by computed tomography and mathematical modelling using haemostatic and inflammatory variables. *Vet J.* 2017;229:6-12.

137. de Laforcade AM, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs with naturally occurring sepsis. *J Vet Intern Med.* 2003;17:674-679.

138. Jessen LR, Wiinberg B, Kjelgaard-Hansen M, et al. Thrombin-activatable fibrinolysis inhibitor activity in healthy and diseased dogs. *Vet Clin Pathol.* 2010;39:296-301.

139. Dircks BH, Mischke R, Schuberth HJ. Platelet-neutrophil aggregate formation in blood samples from dogs with systemic inflammatory disorders. *Am J Vet Res.* 2012;73:939-945.

140. Li RH, Chan DL. Evaluation of platelet function using multiple electrode platelet aggregometry in dogs with septic peritonitis. *J Vet Emerg Crit Care.* 2016;26:630-638.

141. Garosi L, McConnell JE, Platt SR, et al. Results of diagnostic investigations and long-term outcome of 33 dogs with brain infarction (2000-2004). *J Vet Intern Med.* 2005;19:725-731.

142. Paul AE, Lenard Z, Mansfield CS. Computed tomography diagnosis of eight dogs with brain infarction. *Aust Vet J.* 2010;88:374-380.

143. Gredal H, Toft N, Westrup U, et al. Survival and clinical outcome of dogs with ischaemic stroke. *Vet J.* 2013;196:408-413.

144. Fox PR, Keene BW, Lamb K, et al. International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: the REVEAL study. *J Vet Intern Med.* 2018;32:930-943.

145. Hickey MC, Jandrey K, Farrell KS, Carlson-Bremer D. Concurrent diseases and conditions in cats with renal infarcts. *J Vet Intern Med.* 2014;28:319-323.

146. Stokol T, Brooks M, Rush JE, et al. Hypercoagulability in cats with cardiomyopathy. *J Vet Intern Med.* 2008;22:546-552.

147. Schober KE, Maerz I. Assessment of left atrial appendage flow velocity and its relation to spontaneous echocardiographic contrast in 89 cats with myocardial disease. *J Vet Intern Med.* 2006;20:120-130.

148. Peck CM, Nielsen LK, Quinn RL, et al. Retrospective evaluation of the incidence and prognostic significance of spontaneous echocardiographic contrast in relation to cardiac disease and congestive heart failure in cats: 725 cases (2006-2011). *J Vet Emerg Crit Care.* 2016;26:704-712.

149. Payne JR, Borgeat K, Brodbelt DC, et al. Risk factors associated with sudden death vs. congestive heart failure or arterial thromboembolism in cats with hypertrophic cardiomyopathy. *J Vet Cardiol.* 2015;17(Suppl 1):S318-S328.

150. Payne JR, Borgeat K, Connolly DJ, et al. Prognostic indicators in cats with hypertrophic cardiomyopathy. *J Vet Intern Med.* 2013;27:1427-1436.

151. Tarnow I, Falk T, Tidholm A, et al. Hemostatic biomarkers in dogs with chronic congestive heart failure. *J Vet Intern Med.* 2007;21:451-457.

152. Thomas WP, Reed JR, Bauer TG, Breznock EM. Constrictive pericardial disease in the dog. *J Am Vet Med Assoc.* 1984;184:546-553.

153. Van Vleet JF, Ferrans VJ, Weirich WE. Pathologic alterations in congestive cardiomyopathy of dogs. *Am J Vet Res.* 1981;42:416-424.

154. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. *J Thromb Haemost.* 2010;8:2450-2457.

155. Gerotziafas GT, Papageorgiou L, Salta S, et al. Updated clinical models for VTE prediction in hospitalized medical patients. *Thromb Res.* 2018;164(Suppl 1):S62-S69.

156. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e227S-e277S.

157. Merhi Y, Bernier J, Marois Y, Guidoin R. Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: effects of heparin, aspirin, and prostacyclin. *J Cardiovasc Pharmacol.* 1995;26:1-5.

158. Boudreaux MK, Dillon AR, Ravis WR, et al. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. *Am J Vet Res.* 1991;52:1992-1999.

159. Rawlings CA. Pulmonary arteriography and hemodynamics during feline heartworm disease. Effect of aspirin. *J Vet Intern Med.* 1990;4:285-291.

160. Rawlings CA, Farrell RL, Mahood RM. Morphologic changes in the lungs of cats experimentally infected with Dirofilaria immitis. Response to aspirin. *J Vet Intern Med.* 1990;4:292-300.

161. Frederick LG, Suleymanov OD, King LW, et al. The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosis. *Circulation.* 1996;93:129-134.

162. Makkar RR, Litvack F, Eigler NL, et al. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis. *Circulation.* 1997;95:1015-1021.

163. Prosdocimi M, Zatta A, Finesso M. Stenosis and vascular damage as a cause of thrombosis in the dog femoral artery. *Naunyn Schmiedebergs Arch Pharmacol.* 1988;338:430-437.

164. Macdonald A, Busch GJ, Alexander JL, et al. Heparin and aspirin in the treatment of hyperacute rejection of renal allografts in presensitized dogs. *Transplantation.* 1970;9:1-7.

165. Chandler WF, Ercius MS, Ford JW, et al. The effect of heparin reversal after carotid endarterectomy in the dog. A scanning electron microscopy study. *J Neurosurg*. 1982;*56*:97-102.

166. Ercius MS, Chandler WF, Ford JW, Burkel WE. Early versus delayed heparin reversal after carotid endarterectomy in the dog. A scanning electron microscopy study. *J Neurosurg*. 1983;*58*:708-713.

167. Mestre M, Clairefond P, Mardiguian J, et al. Comparative effects of heparin and PK 10169, a low molecular weight fraction, in a canine model of arterial thrombosis. *Thromb Res*. 1985;*38*:389-399.

168. Ljungberg B, Johnsson H. In vivo effects of a low molecular weight heparin fragment on platelet aggregation and platelet dependent hemostasis in dogs. *Thromb Haemost*. 1988;*60*:232-235.

169. Fujii T, Matsuzaki M, Oda T, et al. Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary stenosis. *Jpn Circ J*. 1992;*56*:1191-1197.

170. Jackson CV, Crowe VG, Frank JD, et al. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. *J Pharmacol Exp Ther*. 1992;*261*:546-552.

171. Benedict CR, Ryan J, Todd J, et al. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. *Blood*. 1993;*81*:2059-2066.

172. White BP, Sullivan AT, Lumley P. Prevention of intra-coronary thrombosis in the anaesthetised dog: the importance of thromboxane A2 and thrombin. *Thromb Haemost*. 1994;*71*:366-374.

173. Lynch JJ Jr., Sitko GR, Lehman ED, Vlasuk GP. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. *Thromb Haemost*. 1995;*74*:640-645.

174. Cousins GR, Friedrichs GS, Sudo Y, et al. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. *Circulation*. 1996;*94*:1705-1712.

175. Duval N, Lunven C, O'Brien DP, et al. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin. *Br J Pharmacol*. 1996;*118*:727-733.

176. Roux S, Tschopp T, Baumgartner HR. Effects of napsagatran (Ro 46–6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. *J Pharmacol Exp Ther*. 1996;*277*:71-78.

177. Sudo Y, Lucchesi BR. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin. *J Cardiovasc Pharmacol*. 1996;*27*:545-555.

178. Rebello SS, Miller BV, Basler GC, Lucchesi BR. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. *J Cardiovasc Pharmacol*. 1997;*29*:240-249.

179. Leadley RJ Jr., Kasiewski CJ, Bostwick JS, et al. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin, but not by unfractionated heparin. *Arterioscler Thromb Vasc Biol*. 1998;*18*:908-914.

180. Ohyama T, Hori T, Moriike M, et al. Anti-thrombotic effects of CX-397, a recombinant hirudin analog, in a canine model of coronary artery thrombosis. *Thromb Haemost*. 1998;*79*:423-430.

181. McClanahan TB, Hicks GW, Morrison AL, et al. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. *Eur J Pharmacol*. 2001;*432*:187-194.

182. Rebello SS, Kasiewski CJ, Wang W, et al. Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. *J Cardiovasc Pharmacol*. 2001;*38*:288-297.

183. Viigimaa M, Ohnogi H, Hattori R, et al. Antithrombotic effect and reperfusion by low molecular weight heparin in a canine model of coronary artery thrombosis. *Jpn Circ J*. 1993;*57*:553-557.

184. Smith CE, Rozanski EA, Freeman LM, et al. Use of low molecular weight heparin in cats: 57 cases (1999-2003). *J Am Vet Med Assoc*. 2004;*225*:1237-1241.

185. Borgeat K, Wright J, Garrod O, et al. Arterial thromboembolism in 250 cats in general practice: 2004–2012. *J Vet Intern Med*. 2014;*28*:102-108.

186. Mellett AM, Nakamura RK, Bianco D. A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia. *J Vet Intern Med*. 2011;*25*:71-75.

187. Yao SK, Ober JC, Ferguson JJ, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. *Am J Physiol*. 1994;*267*(2 Pt 2):H488-H493.

188. Hogan DF, Fox PR, Jacob K, et al. Secondary prevention of cardiogenic arterial thromboembolism in the cat: The double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT). *J Vet Cardiol*. 2015;*17*(Suppl 1):S306-S317.

189. Hennan JK, Swillo RE, Morgan GA, et al. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. *Thromb Haemost*. 2006;*95*:469-475.

190. Hong TT, Huang J, Driscoll E, Lucchesi BR. Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. *J Cardiovasc Pharmacol*. 2006;*48*:239-248.

191. Wang K, Zhou X, Huang Y, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. *Thromb Haemost*. 2010;*104*:609-617.

192. Toomey JR, Samanen J, Valocik RE, et al. The antithrombotic efficacy of lotrafiban (SB 214857) in canine models of acute coronary thrombosis. *Curr Drug Targets Cardiovasc Haematol Disord*. 2002;*2*:13-25.

193. Bright JM, Dowers K, Powers BE. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury. *Vet Ther*. 2003;*4*:35-46.

194. Rebello SS, Kasiewski CJ, Bentley RG, et al. Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs. *Thromb Res*. 2001;*102*:261-271.

195. Leadley RJ Jr., Kasiewski CJ, Bostwick JS, et al. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery. *Thromb Haemost*. 1997;*78*:1278-1285.

196. Libersan D, Khalil A, Dagenais P, et al. The low molecular weight heparin, enoxaparin, limits infarct size at reperfusion in the dog. *Cardiovasc Res*. 1998;*37*:656-666.

197. Jun L, Arnout J, Vanhove P, et al. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs. *Coron Artery Dis*. 1995;*6*:257-263.

198. Van De Wiele CM, Hogan DF, Green HW3rd, Sederquist KD. Antithrombotic effect of enoxaparin in clinically healthy cats: a venous stasis model. *J Vet Intern Med*. 2010;*24*:185-191.

199. Schonig JC, Mischke RH. Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats. *Am J Vet Res.* 2016;*77*:700-707.

200. Mischke R, Schmitt J, Wolken S, et al. Pharmacokinetics of the low molecular weight heparin dalteparin in cats. *Vet J.* 2012;*192*:299-303.

201. Mischke R, Schonig J, Doderlein E, et al. Enoxaparin: pharmacokinetics and treatment schedule for cats. *Vet J.* 2014;*200*:375-381.

202. Alwood AJ, Downend AB, Brooks MB, et al. Anticoagulant effects of low-molecular-weight heparins in healthy cats. *J Vet Intern Med.* 2007;*21*:378-387.

203. Vargo CL, Taylor SM, Carr A, Jackson ML. The effect of a low molecular weight heparin on coagulation parameters in healthy cats. *Can J Vet Res.* 2009;*73*:132-136.

204. Rebello SS, Bentley RG, Morgan SR, et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. *Br J Pharmacol.* 2001;*133*:1190-1198.

205. Abendschein DR, Baum PK, Verhallen P, et al. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. *J Pharmacol Exp Ther.* 2001;*296*:567-572.

206. Morassi A, Bianco D, Park E, et al. Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia. *J Vet Emerg Crit Care.* 2016;*26*:488-494.

207. Yang VK, Cunningham SM, Rush JE, de Laforcade A. The use of rivaroxaban for the treatment of thrombotic complications in four dogs. *J Vet Emerg Crit Care.* 2016;*26*:729-736.

208. Conversy B, Blais MC, Dunn M, et al. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma. *Vet J.* 2013;*198*:437-443.

209. Conversy B, Blais MC, Dunn M, et al. Anticoagulant activity of oral rivaroxaban in healthy dogs. *Vet J.* 2017;*223*:5-11.

210. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. *Drug Metab Dispos.* 2009;*37*:1056-1064.

211. Dixon-Jimenez AC, Brainard BM, Brooks MB, et al. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats. *J Vet Emerg Crit Care.* 2016;*26*:619-629.

212. Myers JA, Wittenburg LA, Olver CS, et al. Pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban after oral and intravenous administration to cats. *Am J Vet Res.* 2015;*76*:732-738.

213. Lang D, Freudenberger C, Weinz C. In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. *Drug Metab Dispos.* 2009;*37*:1046-1055.

214. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. *Drug Metab Dispos.* 2009;*37*:1738-1748.

215. He K, Luettgen JM, Zhang D, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. *Eur J Drug Metab Pharmacokinet.* 2011;*36*:129-139.

216. Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. *Drug Metab Dispos.* 2013;*41*:906-915.

217. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. *Thrombosis journal.* 2013;*11*:21-21.

218. Weinkle TK, Center SA, Randolph JF, et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). *J Am Vet Med Assoc.* 2005;*226*:1869-1880.

219. Chiarito M, Cao D, Cannata F, et al. Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis. *JAMA Cardiol.* 2018;*3*:234-241.

220. Schoeman JP. Feline distal aortic thromboembolism: a review of 44 cases (1990-1998). *J Feline Med Surg.* 1999;*1*:221-231.

221. Bush HL Jr., Jakubowski JA, Sentissi JM, et al. Neointimal hyperplasia occurring after carotid endarterectomy in a canine model: effect of endothelial cell seeding vs. perioperative aspirin. *J Vasc Surg.* 1987;*5*:118-125.

222. Escudero-Vela MC, Alvarez L, Rodriguez V, et al. Prevention of the formation of arterial thrombi using different antiplatelet drugs: experimental study in dogs. *Thromb Res.* 1989;*54*:187-195.

223. Escudero MC, Alvarez L, de Haro J, et al. Prevention of thrombus formation on biomaterials exposed to blood using different antiplatelet drugs: experimental study in dogs. *J Biomed Mater Res.* 1994;*28*:1-6.

224. Hernandez-Maldonado JJ, Padberg FT Jr., Teehan E, et al. Arterial intimal flaps: a comparison of primary repair, aspirin, and endovascular excision in an experimental model. *J Trauma.* 1993;*34*(4):565-569; discussion 569–570.

225. Atkins CE, Snyder PS, Keene BW. Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. *J Am Vet Med Assoc.* 1988;*193*:1264-1268.

226. Roux SP, Sakariassen KS, Turitto VT, Baumgartner HR. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models. *Arterioscler Thromb.* 1991;*11*:1182-1191.

227. Yao SK, Benedict CR, Rosolowsky M, et al. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. *J Mol Cell Cardiol.* 1991;*23*:473-482.

228. Mickelson JK, Hoff PT, Homeister JW, et al. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. *J Am Coll Cardiol.* 1993;*21*:502-510.

229. Roux SP, Tschopp TB, Kuhn H, et al. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43–5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. *J Pharmacol Exp Ther.* 1993;*264*:501-508.

230. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. *J Am Coll Cardiol.* 1993;*22*:296-301.

231. Bech FR, Cronenwett JL, McDaniel MD, et al. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency. *J Vasc Surg.* 1990;*12*:119-125.

232. McDaniel MD, Huntsman WT, Miett TO, Cronenwett JL. Effect of a selective thromboxane synthase inhibitor on arterial graft patency and platelet deposition in dogs. *Arch Surg.* 1987;*122*:887-892.

233. Freeman MB, Sicard GA, Valentin LI, et al. The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small-diameter grafts. *J Vasc Surg.* 1988;*7*:554-561.

234. Valentin LI, Sicard GA, Freeman MB, et al. Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts. *Surgery*. 1988;*104*:178-184.

235. Bearn PE, Moffat C, Seddon AM, et al. The effect of platelet inhibitory therapy on prosthetic graft maturation. *Int J Exp Pathol*. 1993;*74*:1-8.

236. Roubin GS, Robinson KA, King SB 3rd, et al. Early and late results of intracoronary arterial stenting after coronary angioplasty in dogs. *Circulation*. 1987;*76*:891-897.

237. Kempczinski RF, Ramalanjaona GR, Douville C, Silberstein EB. Thrombogenicity of a fibronectin-coated, experimental polytetrafluoroethylene graft. *Surgery*. 1987;*101*:439-444.

238. Brothers TE, Vincent CK, Darvishian D, et al. Effects of duration of acetylsalicylic acid administration on patency and anastomotic hyperplasia of ePTFE grafts. *ASAIO Trans*. 1989;*35*:558-560.

239. Matsumoto M, Ban T, Okamoto Y. Behavior of platelets and leukocytes on the luminal surface of small caliber polyurethane grafts. *J Cardiovasc Surg*. 1989;*30*:609-613.

240. De Clerck F, Loots W, Somers Y, et al. 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. *Br J Pharmacol*. 1990;*99*:631-636.

241. Behrend EN, Grauer GF, Greco DS, et al. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. *J Am Anim Hosp Assoc*. 1996;*32*:11-18.

242. Davidson BC, Haggan J. Dietary polyenoic fatty acids change the response of cat blood platelets to inductions of aggregation by ADP. *Prostaglandins Leukot Essent Fatty Acids*. 1990;*39*:31-37.

243. Borenstein N, Gouni V, Behr L, et al. Surgical treatment of cor triatriatum sinister in a cat under cardiopulmonary bypass. *Vet Surg*. 2015;*44*:964-969.

244. Davidson BL, Rozanski EA, Tidwell AS, Hoffman AM. Pulmonary thromboembolism in a heartworm-positive cat. *J Vet Intern Med*. 2006;*20*:1037-1041.

245. Cathcart CJ, Brainard BM, Reynolds LR, et al. Lack of inhibitory effect of acetylsalicylic acid and meloxicam on whole blood platelet aggregation in cats. *J Vet Emerg Crit Care*. 2012;*22*:99-106.

246. Parton K, Balmer TV, Boyle J, et al. The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. *J Vet Pharmacol Ther*. 2000;*23*:73-79.

247. Satoh H, Amagase K, Takeuchi K. The role of food for the formation and prevention of gastrointestinal lesions induced by aspirin in cats. *Dig Dis Sci*. 2013;*58*:2840-2849.

248. Bjorkman JA, Zachrisson H, Forsberg GB, et al. High-dose aspirin in dogs increases vascular resistance with limited additional antiplatelet effect when combined with potent P2Y12 inhibition. *Thromb Res*. 2013;*131*:313-319.

249. Hasa AA, Schmaier AH, Warnock M, et al. Thrombostatin inhibits cyclic flow variations in stenosed canine coronary arteries. *Thromb Haemost*. 2001;*86*:1296-1304.

250. Hong TT, Huang J, Driscoll E, Lucchesi BR. The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). *J Cardiovasc Pharmacol*. 2005;*46*:526-533.

251. Nylander S, Wagberg F, Andersson M, et al. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase beta inhibition and aspirin in man. *J Thromb Haemost*. 2015;*13*:1494-1502.

252. Ravnefjord A, Weilitz J, Emanuelsson BM, van Giezen JJ. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. *Thromb Res*. 2012;*130*:622-628.

253. van Giezen JJ, Berntsson P, Zachrisson H, Bjorkman JA. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. *Thromb Res*. 2009;*124*:565-571.

254. Wang YX, Vincelette J, da Cunha V, et al. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. *Thromb Haemost*. 2007;*97*:847-855.

255. Abid M, Kalbantner K, Mischke R. Influence of test time on results of the impedance aggregometer multiplate analyser in dogs. *Comp Clin Pathol*. 2014;*23*:1387-1393.

256. Borgarelli M, Lanz O, Pavlisko N, et al. Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study. *J Vet Cardiol*. 2017;*19*:256-267.

257. Brainard BM, Kleine SA, Papich MG, Budsberg SC. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. *Am J Vet Res*. 2010;71:822-830.

258. Thames BE, Lovvorn J, Papich MG, et al. The effects of clopidogrel and omeprazole on platelet function in normal dogs. *J Vet Pharmacol Ther*. 2017;*40*:130-139.

259. Yao SK, Ober JC, Ferguson JJ, et al. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. *Circulation*. 1992;*86*:1993-1999.

260. Hogan DF, Andrews DA, Green HW, et al. Antiplatelet effects and pharmacodynamics of clopidogrel in cats. *J Am Vet Med Assoc*. 2004;*225*:1406-1411.

261. den Toom ML, van Leeuwen MW, Szatmari V, Teske E. Effects of clopidogrel therapy on whole blood platelet aggregation, the plateletworks(R) assay and coagulation parameters in cats with asymptomatic hypertrophic cardiomyopathy: a pilot study. *Vet Q*. 2017;*37*:8-15.

262. Teuber M, Mischke R. Influence of a low dosage of clopidogrel on platelet function in cats as measured by the platelet function analyser PFA-100 and the multiplate analyser. *Res Vet Sci*. 2016;*109*:149-156.

263. Hamel-Jolette A, Dunn M, Bedard C. Plateletworks: a screening assay for clopidogrel therapy monitoring in healthy cats. *Can J Vet Res*. 2009;*73*:73-76.

264. Ho KK, Abrams-Ogg AC, Wood RD, et al. Assessment of platelet function in healthy cats in response to commonly prescribed antiplatelet drugs using three point-of-care platelet function tests. *J Feline Med Surg*. 2017;*19*:638-647.

265. Li RH, Stern JA, Ho V, et al. Platelet activation and clopidogrel effects on ADP-induced platelet activation in cats with or without the A31P mutation in MYBPC3. *J Vet Intern Med*. 2016;*30*:1619-1629.

266. Shen C, Huang X, Li J, et al. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. *Xenobiotica*. 2016;*46*:530-541.

267. Choppin A, Irwin I, Lach L, et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. *Br J Pharmacol*. 2009;*158*:1536-1547.

268. Monnet E, Morgan MR. Effect of three loading doses of warfarin on the international normalized ratio for dogs. *Am J Vet Res*. 2000;*61*:48-50.

269. Makutani S, Kichikawa K, Uchida H, et al. Effect of antithrombotic agents on the patency of PTFE-covered stents in the inferior vena cava: an experimental study. *Cardiovasc Intervent Radiol*. 1999;*22*:232-238.

270. Hoffman MJ, Stewart JR, Greenfield LJ. Effects of coumadin on the resolution of canine venous thrombi. *J Surg Res*. 1986;*40*:1-5.

271. Hoak JC, Connor WE, Warner ED. The antithrombotic effects of sodium heparin and sodium warfarin. *Arch Intern Med*. 1966;*117*:25-31.

272. Lantz GC, Badylak SF, Coffey AC, et al. Small intestinal submucosa as a superior vena cava graft in the dog. *J Surg Res*. 1992;*53*:175-181.

273. Arai S, Griffiths LG, Mama K, et al. Bioprosthesis valve replacement in dogs with congenital tricuspid valve dysplasia: technique and outcome. *J Vet Cardiol*. 2011;*13*:91-99.

274. Arai S, Callan MB. Warfarin therapy in a dog with acute arterial thrombosis and pyometra. *Can Vet J*. 2014;*55*:1066-1068.

275. Dale J, Aasen AO, Resch F, et al. Mitral disc valve implantation in the dog: early and late valve thrombosis and its prevention. *Eur Surg Res*. 1983;*15*:249-255.

276. Orton EC, Hackett TB, Mama K, Boon JA. Technique and outcome of mitral valve replacement in dogs. *J Am Vet Med Assoc*. 2005;*226*:1508-1511, 1500.

277. Todd RS, Sive EB, Dejode LR, et al. Replacement of segments of the venous system. *Arch Surg*. 1963;*87*:998-1002.

278. Covell DG, Abbrecht PH, Powers WF. Changes in the pharmacology of warfarin during long-term administration in dogs. *J Lab Clin Med*. 1984;*103*:272-283.

279. Neff-Davis CA, Davis LE, Gillette EL. Warfarin in the dog: pharmacokinetics as related to clinical response. *J Vet Pharmacol Ther*. 1981;*4*:135-140.

280. Smith SA, Kraft SL, Lewis DC, et al. Pharmacodynamics of warfarin in cats. *J Vet Pharmacol Ther*. 2000;*23*:339-344.

281. Pouchelon JL, Chetboul V, Devauchelle P, et al. Diagnosis of pulmonary thromboembolism in a cat using echocardiography and pulmonary scintigraphy. *Journal of Small Animal Practice*. 1997;*38*:306-310.

282. Piegras DG, Sundt TM, Jr., Didisheim P. Effect of anticoagulants and inhibitors of platelet aggregation on thrombotic occlusion of endarterectomized cat carotid arteries. *Stroke*. 1976;*7*:248-254.

283. Smith SA, Kraft SL, Lewis DC, Freeman LC. Plasma pharmacokinetics of warfarin enantiomers in cats. *J Vet Pharmacol Ther*. 2000;*23*:329-337.

284. Koyama H, Matsumoto H, Fukushima RU, Hirose H. Local intra-arterial administration of urokinase in the treatment of a feline distal aortic thromboembolism. *J Vet Med Sci*. 2010;*72*:1209-1211.

285. Diquelou A, Barbaste C, Gabaig AM, et al. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs. *Vet Clin Pathol*. 2005;*34*:237-242.

286. Helmond SE, Polzin DJ, Armstrong PJ, et al. Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs. *J Vet Intern Med*. 2010;*24*:597-605.

287. Morris TA, Marsh JJ, Konopka R, et al. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. *Thromb Res*. 2000;*100*:185-194.

288. Scott KC, Hansen BD, DeFrancesco TC. Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis. *J Vet Emerg Crit Care*. 2009;*19*:74-80.

289. Erickson M, Hiebert LM, Carr AP, Stickney JD. Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs. *Can J Vet Res*. 2014;*78*:193-201.

290. Manion JS, Thomason JM, Langston VC, et al. Anticoagulant effects of inhaled unfractionated heparin in the dog as determined by partial thromboplastin time and factor Xa activity. *J Vet Emerg Crit Care*. 2016;*26*:132-136.

291. Scott KC, Hansen BD, DeFrancesco TC. Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis. *J Vet Emerg Crit Care*. 2009;*19*:74-80.

292. Gara-Boivin C, Del Castillo JRE, Dunn ME, Bedard C. Effect of dalteparin administration on thrombin generation kinetics in healthy dogs. *Vet Clin Pathol*. 2017;*46*:269-277.

293. Lynch AM, deLaforcade AM, Sharp CR. Clinical experience of anti-Xa monitoring in critically ill dogs receiving dalteparin. *J Vet Emerg Crit Care*. 2014;*24*:421-428.

294. Lunsford KV, Mackin AJ, Langston VC, Brooks M. Pharmacokinetics of subcutaneous low molecular weight heparin (enoxaparin) in dogs. *J Am Anim Hosp Assoc*. 2009;*45*:261-267.

295. Panek CM, Nakamura RK, Bianco D. Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases. *J Vet Emerg Crit Care*. 2015;*25*:273-277.

296. Rhue KE, Taylor AR, Cole RC, Winter RL. Bilateral vertebral venous sinus thrombosis causing cervical spinal cord compression in a dog. *Front Vet Sci*. 2017;*4*:8.

297. Gregory CR, Kyles AE, Bernsteen L, Mehl M. Results of clinical renal transplantation in 15 dogs using triple drug immunosuppressive therapy. *Vet Surg*. 2006;*35*:105-112.

298. Pouzot-Nevoret C, Barthelemy A, Cluzel M, et al. Enoxaparin has no significant anticoagulation activity in healthy Beagles at a dose of 0.8 mg/kg four times daily. *Vet J*. 2016;*210*:98-100.

299. Fiakpui NN, Hogan DF, Whittem T, et al. Dose determination of fondaparinux in healthy cats. *Am J Vet Res*. 2012;*73*:556-561.

300. Greene CE. Effects of aspirin and propranolol on feline platelet aggregation. *Am J Vet Res*. 1985;*46*:1820-1823.

301. Allen DG, Johnstone IB, Crane S. Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat. *Am J Vet Res*. 1985;*46*:660-663.

302. Lantz GC, Badylak SF, Coffey AC, et al. Small intestinal submucosa as a small-diameter arterial graft in the dog. *J Invest Surg*. 1990;*3*:217-227.

303. Mischke R, Grebe S, Jacobs C, Kietzmann M. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. *Am J Vet Res*. 2001;*62*:595-598.

304. Pittman JR, Koenig A, Brainard BM. The effect of unfractionated heparin on thrombelastographic analysis in healthy dogs. *J Vet Emerg Crit Care*. 2010;*20*:216-223.

305. Babski DM, Brainard BM, Ralph AG, et al. Sonoclot(R) evaluation of single- and multiple-dose subcutaneous unfractionated heparin therapy in healthy adult dogs. *J Vet Intern Med*. 2012;*26*:631-638.

306. Dixon-Jimenez AC, Brainard BM, Cathcart CJ, Koenig A. Evaluation of a point-of-care coagulation analyzer (Abaxis VSPro) for identification of coagulopathies in dogs. *J Vet Emerg Crit Care*. 2013;*23*:402-407.

307. McLaughlin CM, Marks SL, Dorman DC, et al. Thromboelastographic monitoring of the effect of unfractionated heparin in healthy dogs. *J Vet Emerg Crit Care*. 2017;*27*:71-81.

308. Ignasiak DP, McClanahan TB, Bousley RE, et al. Effects of intravenous enoxaparin and intravenous inogatran in an electrolytic injury model of venous thrombosis in the dog. *J Thromb Thrombolysis*. 1998;6:199-206.

309. Brainard BM, Koenig A, Babski DM, et al. Viscoelastic pharmacodynamics after dalteparin administration to healthy dogs. *Am J Vet Res*. 2012;73:1577-1582.

310. Mischke R, Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin. *Res Vet Sci*. 2000;69:241-247.

311. Gara-Boivin C, Del Castillo JRE, Dunn ME, Bedard C. In vitro effects of dalteparin on thrombin generation in canine plasma. *Vet Clin Pathol*. 2017;46:442-450.

312. Mestre M, Uzan A, Sedivy P, Cavero I. Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability. *Thromb Res*. 1992;66:191-206.

313. Mischke R, Fehr M, Nolte I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. *Res Vet Sci*. 2005;79:69-76.

314. Anderson K, Jupiter DC, Abernathy SW, Frazee RC. Should clopidogrel be discontinued before laparoscopic cholecystectomy? *Am J Surg*. 2014;208:926-931; discussion 930-921.

315. Akhavan-Sigari R, Rohde V, Abili M. Continuation of medically necessary platelet aggregation inhibitors—acetylsalicylic acid and clopidogrel—during surgery for spinal degenerative disorders: results in 100 patients. *Surg Neurol Int*. 2014;5(Suppl 7):S376-S379.

316. Abdel Samie A, Stumpf M, Sun R, Theilmann L. Biliary-pancreatic endoscopic and surgical procedures in patients under dual antiplatelet therapy: a single-center study. *Clin Endosc*. 2013;46:395-398.

317. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. *J Intern Med*. 2005;257:399-414.

318. Gandhi S, Narula N, Mosleh W, et al. Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy. *Aliment Pharmacol Ther*. 2013;37:947-952.

319. Lee J, Jung CW, Jeon Y, et al. Effects of preoperative aspirin on perioperative platelet activation and dysfunction in patients undergoing off-pump coronary artery bypass graft surgery: a prospective randomized study. *PLoS One*. 2017;12:e0180466.

320. Joseph B, Rawashdeh B, Aziz H, et al. An acute care surgery dilemma: emergent laparoscopic cholecystectomy in patients on aspirin therapy. *Am J Surg*. 2015;209:689-694.

321. Wild JB, Dattani N, Stather P, et al. Effect of anticoagulation and antiplatelet therapy on incidence of endoleaks and sac size expansions after endovascular aneurysm repair. *Ann Vasc Surg*. 2014;28:554-559.

322. Toepfer NJ, Baylor K, Henry Y, et al. The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. *Urology*. 2013;82:773-779.

323. Antolovic D, Rakow A, Contin P, et al. A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery–the APAP trial (ISRCTN45810007). *Langenbecks Arch Surg*. 2012;397:297-306.

324. Badreldin A, Kroener A, Kamiya H, et al. Effect of clopidogrel on perioperative blood loss and transfusion in coronary artery bypass graft surgery. *Interact Cardiovasc Thorac Surg*. 2010;10:48-52.

325. Cao C, Indraratna P, Ang SC, et al. Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis. *J Thorac Cardiovasc Surg*. 2014;148:3092-3098.

326. Chu EW, Chernoguz A, Divino CM. The evaluation of clopidogrel use in perioperative general surgery patients: a prospective randomized controlled trial. *Am J Surg*. 2016;211:1019-1025.

327. Goldhammer JE, Herman CR, Berguson MW, et al. Preoperative aspirin does not increase transfusion or reoperation in isolated valve surgery. *J Cardiothorac Vasc Anesth*. 2017;31:1618-1623.

328. Kumar V, Mitchell MD, Umscheid CA, et al. Risk of complications with use of aspirin during renal biopsy: a systematic review. *Clin Nephrol*. 2018;89:67-76.

329. Oscarsson A, Gupta A, Fredrikson M, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. *Br J Anaesth*. 2010;104:305-312.

330. Deja MA, Kargul T, Domaradzki W, et al. Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. *J Thorac Cardiovasc Surg*. 2012;144:204-209.

331. Girotra C, Padhye M, Mandlik G, et al. Assessment of the risk of haemorrhage and its control following minor oral surgical procedures in patients on anti-platelet therapy: a prospective study. *Int J Oral Maxillofac Surg*. 2014;43:99-106.

332. Lillis T, Ziakas A, Koskinas K, et al. Safety of dental extractions during uninterrupted single or dual antiplatelet treatment. *Am J Cardiol*. 2011;108:964-967.

333. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e326S-e350S.

334. Flevas DA, Megaloikonomos PD, Dimopoulos L, et al. Thromboembolism prophylaxis in orthopaedics: an update. *EFORT Open Rev*. 2018;3:136-148.

335. Rao GH, Johnson GJ, Reddy RK, White JG. Rapid return of cyclo-oxygenase active platelets in dogs after a single oral dose of aspirin. *Prostaglandins*. 1981;22:761-772.

336. Joo MS, Ahn BM, Kim HJ, et al. Evaluation of feasible timing of elective noncardiac procedure after antiplatelet discontinuation in patients treated with antiplatelet agents. *J Investig Med*. 2014;62:808-812.

337. Gulpinar K, Ozdemir S, Ozis E, et al. A preliminary study: aspirin discontinuation before elective operations; when is the optimal timing? *J Korean Surg Soc*. 2013;85:185-190.

338. Zisman E, Erport A, Kohanovsky E, et al. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients. *Eur J Anaesthesiol*. 2010;27:617-623.

339. Firanescu CE, Martens EJ, Schonberger JP, et al. Postoperative blood loss in patients undergoing coronary artery bypass surgery after preoperative treatment with clopidogrel. A prospective randomised controlled study. *Eur J Cardiothorac Surg*. 2009;36:856-862.

340. Chernoguz A, Telem DA, Chu E, et al. Cessation of clopidogrel before major abdominal procedures. *Arch Surg*. 2011;146:334-339.

341. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. *Blood*. 2000;95:2514-2522.

342. Heilmann E, Friese P, Anderson S, et al. Biotinylated platelets: a new approach to the measurement of platelet life span. *Br J Haematol.* 1993;*85*:729-735.

343. Jacobs RM, Boyce JT, Kociba GJ. Flow cytometric and radioisotopic determinations of platelet survival time in normal cats and feline leukemia virus-infected cats. *Cytometry.* 1986;*7*:64-69.

344. Nouraei SM, Gholipour Baradari A, Emami Zeydi A. Does early post-operative administration of aspirin influence the risk of bleeding after coronary artery bypass graft surgery? A prospective observational study. *Med Arch.* 2015;*69*:381-383.

345. Hijazi EM, Musleh GS. Clopidogrel within few hours of coronary artery bypass grafting does significantly increase the risk of bleeding. *Cardiol Res.* 2012;*3*:209-213.

346. Alghamdi AA, Moussa F, Fremes SE. Does the use of preoperative aspirin increase the risk of bleeding in patients undergoing coronary artery bypass grafting surgery? Systematic review and meta-analysis. *J Card Surg.* 2007;*22*:247-256.

347. Al-Lawati AA, Muthuswamy V. Continuing aspirin causes higher drainage even under full protection with antifibrinolytics. *Thorac Cardiovasc Surg.* 2013;*61*:726-730.

348. Chow B, French A. Conversion of atrial fibrillation after levothyroxine in a dog with hypothyroidism and arterial thromboembolism. *J Small Anim Pract.* 2014;*55*:278-282.

349. DePaula KM, deLaorcade AM, King RG, et al. Arterial thrombosis after vehicular trauma and humeral fracture in a dog. *J Am Vet Med Assoc.* 2013;*243*:394-398.

350. Kim JH, Park HM. Unilateral femoral arterial thrombosis in a dog with malignant mammary gland tumor: clinical and thermographic findings, and successful treatment with local intra-arterial administration of streptokinase. *J Vet Med Sci.* 2012;*74*:657-661.

351. Singh A, Brisson BA. Chylothorax associated with thrombosis of the cranial vena cava. *Can Vet J.* 2010;*51*:847-852.

352. Bliss SP, Bliss SK, Harvey HJ. Use of recombinant tissue-plasminogen activator in a dog with chylothorax secondary to catheter-associated thrombosis of the cranial vena cava. *J Am Anim Hosp Assoc.* 2002;*38*:431-435.

353. Ageno W, Samperiz A, Caballero R, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. *Thromb Res.* 2015;*135*:666-672.

354. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. *Blood.* 2014;*123*:1794-1801.

355. Cunningham SM, Ames MK, Rush JE, Rozanski EA. Successful treatment of pacemaker-induced stricture and thrombosis of the cranial vena cava in two dogs by use of anticoagulants and balloon venoplasty. *J Am Vet Med Assoc.* 2009;*235*:1467-1473.

356. Mulz JM, Kraus MS, Thompson M, Flanders JA. Cranial vena caval syndrome secondary to central venous obstruction associated with a pacemaker lead in a dog. *J Vet Cardiol.* 2010;*12*:217-223.

357. Ngwenyama TR, Herring JM, O'Brien M, et al. Contrast-enhanced multidetector computed tomography to diagnose pulmonary thromboembolism in an awake dog with pyothorax. *J Vet Emerg Crit Care.* 2014;*24*:731-738.

358. Pouchelon JL, Chetboul V, Devauchelle P, et al. Diagnosis of pulmonary thromboembolism in a cat using echocardiography and pulmonary scintigraphy. *J Small Anim Pract.* 1997;*38*:306-310.

359. Sobel KE, Williams JE. Pneumothorax secondary to pulmonary thromboembolism in a dog. *J Vet Emerg Crit Care.* 2009;*19*:120-126.

360. Mays EM, Dorman DC, McKendry C, Hanel RM. A pilot study documenting increased thrombin generation following abrupt withdrawal of heparin therapy in healthy dogs. *J Vet Emerg Crit Care.* 2018;*28*:518-526.

361. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. *N Engl J Med.* 1992;*327*:141-145.

362. Becker RC, Spencer FA, Li Y, et al. Thrombin generation after the abrupt cessation of intravenous unfractionated heparin among patients with acute coronary syndromes: potential mechanisms for heightened prothrombotic potential. *J Am Coll Cardiol.* 1999;*34*:1020-1027.

363. Bijsterveld NR, Peters RJ, Murphy SA, et al. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. *J Am Coll Cardiol.* 2003;*42*:2083-2089.

364. Di Tano G, Mazzu A. Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. *Br Heart J.* 1995;*74*:131-133.

365. Bijsterveld NR, Moons AH, Meijers JC, et al. Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. *J Am Coll Cardiol.* 2002;*39*:811-817.

366. Goodman SG, Barr A, Sobtchouk A, et al. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q-wave myocardial infarction: the Canadian ESSENCE ST segment monitoring substudy. *J Am Coll Cardiol.* 2000;*36*:1507-1513.

367. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. *Circulation.* 1998;*97*:251-256.

368. Hansen JB, Naalsund T, Sandset PM, Svensson B. Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. *Thromb Res.* 2000;*100*:413-417.

369. Nagasayi S, Varman S, Ting YY, Ang W. Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: a case report. *Age Ageing.* 2017;*46*:870-871.

370. Agarwal A, Patel A, Mufti O, et al. Rivaroxaban rebound acute coronary event: a post marketing experience. *Cardiol Res.* 2013;*4*:207-210.

371. Gondor G, Stollberger C. Pulmonary embolism four days after interruption of therapy with rivaroxaban. *Hamostaseologie.* 2017;*37*:302-306.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.